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The tumour suppressor protein p53 is a critical protein in the DNA damage checkpoint 
pathway. It acts as a transcription factor that is involved in initiating the apoptotic pathway; 
disruption of this pathway can lead to various forms of cancer. Due to its importance in 
cancer prevention, p53 has been extensively studied, though only a small fraction of these 
studies have been in non-mammalian models. Some previous studies of p53 expression and 
regulation in lower vertebrate species have shown potential differences in its control, in 
comparison to the better characterized mammalian pathways. These differences emphasize 
the need to further investigate its mechanism of action in lower vertebrate models. To 
evaluate its biomarker potential for aquatic toxicology studies, two rainbow trout cell lines 
(RTbrain-W1 and RTgill-W1) were used in dose response experiments using DNA damage 
checkpoint inducing agents: bleomycin, hydroxyurea, and methyl methanesulfonate. For our 
studies, a rainbow trout specific polyclonal antibody was developed using purified 
recombinant rainbow trout p53. The purified antibody was shown to be successful in 
detecting p53 in rainbow trout cell lines and tissues. Our results show that rainbow trout p53 
is not induced by checkpoints initiated by different types of DNA damage. These results infer 
the possibility of an alternate mechanism of DNA damage checkpoint reaction in these cell 
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1.1 DNA damage checkpoint 
DNA damage is a common occurrence in the cell that can lead to mutations and cancer. To 
protect against the onslaught of DNA damage, eukaryotic cells have DNA damage response 
pathways which are composed of cell cycle checkpoints, DNA damage repair, and apoptosis 
(Sancar et al., 2004). When cell cycle checkpoints are activated, cell cycle arrest is initiated, 
allowing time for DNA damage repair. In situations where the damage is too extensive to be 
repaired efficiently, cells can undergo apoptosis. In the DNA damage response pathways, 
there are several main types of proteins that are involved in leading the cells to the desired 
outcome. Due to the complexity of these pathways, various proteins function at multiple 
points in the pathways. Based on their function, proteins in the DNA damage checkpoint are 
loosely grouped into the categories of sensors, transducers, mediators, and effectors (Niida 
and Nakanishi, 2006), representing the flow of signals in the DNA damage checkpoint 
(Figure 1.1). There are several lines of thought that exist for categorizing these proteins that 
can be based on chronological activation, as well as function. It seems that many proteins in 
the pathway have multiple roles, and depending on the stage of DNA damage checkpoint 
activation, the proteins could have roles that transition from one role to the next. The main 





Figure 1.1 The DNA damage response pathway 
The DNA damage response pathway is composed of many proteins that are grouped loosely 
into the categories of sensors, mediators, transducers, and effectors. Sensors are localized to 
sites of DNA damage and are able to activate downstream transducers with the assistance of 
mediator proteins. The transducers are then able to activate downstream effector proteins. 
Arrows represent interactions between the proteins in each category and the bottom row 





Figure 1.2 The DNA damage checkpoint 
The DNA damage checkpoint is composed of many proteins. The diagram here represents 
the main interactions in the mammalian pathway, which are initiated upon DNA damage. 
Solid arrows represent positive interactions between the proteins. Dotted arrows represent 






During the cell cycle, there are several types of changes in DNA that could initiate a DNA 
damage checkpoint. These changes could include double strand breaks, single strand breaks, 
and stalled replication forks. Depending on the type of change, different sensor proteins can 
be activated and localized to the site of damage (Bartek and Lukas, 2007). The 9-1-1 
complex which is composed of Rad9, Hus1, and Rad1 is essential for the detection of DNA 
damage (Qin and Li, 2003). The 9-1-1 complex is similar in structure to the homotrimeric 
sliding clamp protein, proliferating nuclear antigen (PCNA) (Venclovas and Thelen, 2000). 
While both the 9-1-1 complex and PCNA have similar roles as sliding clamps, they are active 
under different circumstances. The PCNA complex is loaded onto DNA by the RFC 
(replication factor C) complex during regular DNA replication and serves as a sliding 
scaffold for the tethering of replication proteins (Moldovan et al., 2007). This RFC complex 
is composed of 5 subunits (p36, p37, p39, p40, and p140). Alternatively, the 9-1-1 complex 
is loaded onto the DNA in response to DNA damage with the help of the Rad17-RFC 
(Rad17-replication factor C) checkpoint clamp loader complex which contains Rad17 in 
place of p140 (Parrilla-Castellar et al., 2004). The activation of the 9-1-1 complex has been 
shown in the presence of alkylation, ultraviolet light, ionizing radiation, and stalled 
replication (Parrilla-Castellar et al., 2004). This formation of the Rad17-RFC/9-1-1 
checkpoint complex is one of the early steps in the initiation of the DNA damage checkpoint 
response. 
For detection of double strand breaks (DSBs), the MRN complex (Mre11-Rad50-
Nbs1) is localized to regions of DSBs, through the recognition of DNA by the Rad50 subunit 
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(Van Den Bosch et al., 2003). The MRN complex is thought to be an upstream sensor 
complex because of its early localization to DSBs. Its recruitment to DSBs is also 
independent of other proteins in the DNA damage response checkpoint, which is another 
factor contributing to its categorization as a sensor complex. The localization of the Nbs1 
subunit to sites of DSBs is also required for the downstream recruitment of ATM (ataxia 
telengiectasia mutated). ATM is a component of the PIKK (phosphoinositide 3-kinase related 
kinases) family of kinases, which also includes ATR (ATM and Rad3 related) and DNA-PK 
(DNA-dependent protein kinase) (Ackermann and El-Deiry, 2008). ATM and ATR are 
known as both sensors and transducers in the DNA damage checkpoint pathway. Once ATM 
has been recruited to the DSBs by the MRN complex, several events are initiated that result 
in local conformational changes in the DNA. This change in the structure of DNA is thought 
to facilitate the subsequent DNA checkpoint signalling and DNA repair events. To begin this 
process, the PIKK kinases phosphorylate serine139 of the histone protein H2AX, which acts 
as a scaffold for the mediator protein MDC1 (mediator of damage checkpoint protein 1). 
While bound directly to γH2AX, MDC1 will then also interact with the Nbs1 subunit of the 
MRN complex. Together, these processes allow for continued H2AX phosphorylation. These 
changes in chromatin conformation and foci formation also lead to the autophosphorylation 
of ATM.  
Along with the recruitment of ATM, ATR is also recruited to sites of DNA damage 
through the presence of ssDNA. When genotoxic stress is present, large stretches of single-
stranded DNA can be generated which are coated in RPA (replication protein A) (Zou and 
Elledge, 2003). ATR senses stretches of RPA coated ssDNA that may be a result of single-
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stranded breaks (SSBs), replication fork stalling, or DNA lesions caused by DSB resection. 
ATR is localized to sites of ssDNA through forming a complex with ATRIP (ATR-
interacting protein). After recruitment to the ssDNA, it is bound to the DNA through ATR-
ATRIP oligomerization and interaction with RPA (Ackermann and El-Deiry, 2008), though 
this localization is not sufficient for activation of the complex (MacDougall et al., 2007). It 
has been shown that the interaction of the ATR-ATRIP complex with TopBP1 (DNA 
topoisomerase IIβ binding protein I) is necessary for the activation of ATR once it is 
localized. Once activated, ATR is able to phosphorylate downstream proteins to propagate 
the kinase signal cascade.  
While the 9-1-1 complex and the ATR-ATRIP complex are recuited to DNA 
independently, the presence of the 9-1-1 complex facilitates the ATR-mediated 
phosphorylation of the downstream transducer kinase Chk1 (Weiss et al., 2002). These 
results indicate that while the initiation events of each pathway may be separate, interaction 
between the pathways may still be required. 
1.1.2 Mediators 
Mediators are proteins that act as recruiters and scaffold components for other components in 
the DNA damage checkpoint pathway and can modulate the activity of ATM/ATR, as well 
as facilitate interactions between kinases and their substrates (Kastan and Bartek, 2004). The 
MRN complex mentioned above is also occasionally thought of as a mediator protein, due to 
its function as a scaffold for other proteins, though its early recruitment to the sites of DNA 
damage indicate that it functions mainly as a sensor. MDC1 is one of the main mediator 
proteins, and was briefly mentioned above. The phosphorylation of H2AX is thought to be 
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sustained by MDC1, possibly through retention of ATM. Together, these proteins act as a 
scaffold to help form foci with other mediators such as 53BP1 (p53 binding protein 1), 
Claspin, and BRCA1 (Kastan and Bartek, 2004). Along with phosphorylation, ubiquitination 
also plays a role in generating mediator foci at sites of DSBs. The E3 ubiquitin ligase Ubc-
13-Rnf8 is recruited by the phosphorylated form of MDC1, and is then able to ubiquitinate 
H2AX. Along with the E3 ubiquitin ligase, BRCA1 also plays a role in the ubiquitination of 
proteins at the foci (Starita and Parvin, 2003). Through phosphorylation, ubiquitination, and 
the formation of foci, the mediator group of proteins help to facilitate the interactions 
between the other proteins and substrates in the DNA damage pathway.  
1.1.3 Transducers 
The transducer category consists of protein kinases that are activated in the presence of DNA 
damage, which then participate in the signalling cascades that result in an amplification of 
the original DNA damage signal. Though both ATM and ATR were mentioned earlier in the 
sensor category, they are both also commonly characterized as transducer proteins. 
Temporally, they respond early in the DNA damage response, indicative of many sensor 
proteins. However, their critical role in perpetuating the kinase cascade is considered as part 
of their role as transducers. While ATM and ATR are structurally similar large proteins, they 
carry out distinct roles in the DNA damage response pathway. ATM is mainly activated in 
response to DSBs, whereas ATR is activated in response to DNA replication stress that 
results in abnormally long stretches of ssDNA (Ackermann and El-Deiry, 2008). ATR can be 




ATM is activated through phosphorylation at several sites in response to DSBs. Its 
inactive form is found as dimers or higher-ordered oligomers, which prevents it from binding 
to downstream substrates. Autophosphorylation of Ser1981 allows the deoligomerization of 
ATM oligomers, releasing monomers of ATM which can now interact with downstream 
substrates (Bakkenist and Kastan, 2003). This autophosphorylation was seen in HEK-293T 
cells but the site is also conserved in both mouse and Xenopus ATM. Other sites have also 
been implicated in phosphorylation events involved with ATM signalling, such as the 
autophosphorylation of Ser367 and Ser1893 in human lyphoblastoid cell lines (Kozlov et al., 
2006). While phosphorylation of these sites has been shown to monomerize ATM and aid in 
signalling, other research has shown that these phosphorylation events may not be necessary. 
ATM has been found in monomeric states, without phosphorylation at Ser1981 (Dupré et al., 
2006) and mutational studies in mice have shown that mutation of Ser1987 (mouse 
equivalent of Ser1981) does not abolish the response of ATM-dependent pathways 
(Pellegrini et al., 2006). While these phosphorylation events do not appear to be essential for 
ATM activation, induction of these events have been shown in response to DNA damage 
induced by ionizing radiation (Bakkenist and Kastan, 2003). Once ATM has been recruited 
to sites of DNA damage and has been activated through phosphorylation, it can initiate the 
kinase cascade of downstream pathways through phosphorylation of various substrates 
including H2AX, Nbs1, BRCA1, MDC1, Chk2, Mdm2, and p53 (Ackermann and El-Deiry, 
2008). H2AX, Nbs1, BRCA1, and MDC1 were mentioned above as early responders to DNA 
damage. These proteins help to form the initial scaffold for foci formation which facilitates 
the interactions between transducers and their substrates. Chk2, another transducer protein, 
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can also be phosphorylated by ATM, and is discussed in further detail below. ATM is also 
able to phosphorylate p53, which is a downstream effector protein. Phosphorylation of p53 
and its negative regulator Mdm2 results in an inhibition of interaction between the two 
proteins, which in turn, stabilizes and activates p53 (Hock and Vousden, 2010). The 
mechanisms of this will be discussed in further detail later in this chapter. Mutations that 
compromise the function of ATM result in defective responses to specific types of DNA 
damage, which is a characteristic of the disease ataxia telangiectasia (McKinnon, 2004). 
Though ATM is a key part of the DNA damage response pathway, knockdown of ATM in 
mice has shown that ATM is not essential for viability in this organism (Barlow et al., 1996). 
Unlike ATM which functions in a monomeric state, ATR exists in a complex with 
ATRIP and is activated through interaction with TopBP1 (Mordes and Cortez, 2008). ATRIP 
is essential for ATR signalling and aids in the localization of ATR to site of DNA damage 
(Cortez et al., 2001). TopBP1, which is necessary for ATR activation, is localized to sites of 
DNA damage through the 9-1-1 complex independently of ATR (Delacroix et al., 2007). 
Cimprich and Cortez (Cimprich and Cortez, 2008) hypothesized that this independent 
recruitment of TopBP1 and ATR-ATRIP to sites of DNA-damage reduces the probability of 
inappropriate initiation of checkpoints, due to the requirement of two independent 
recruitment events.  With both TopBP1 and ATR-ATRIP localized to the site of damage, 
TopBP1 is then able to activate the kinase activity of the ATR-ATRIP complex (Kumagai et 
al., 2006). Since TopBP1 is a substrate of ATM, phosphorylation of TopBP1 by ATM can 
activate ATR in response to DSBs (Yoo et al., 2007). While it is known that TopBP1 is 
required for ATR-ATRIP activation, the exact mechanisms are not as clear. It has been 
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shown that TopBP1 activates the ATR-ATRIP complex primarily through binding with 
ATRIP, though there are specific amino acids within ATR that are necessary for activation 
by TopBP1 (Cimprich and Cortez, 2008). Once activated, ATR is able to phosphorylate 
many substrates including ATRIP and TopBP1, which increases the kinase activity of ATR 
(Itakura et al., 2004; Kumagai et al., 2006). ATR is also involved in the phosphorylation of 
Nbs1 and H2AX for amplification of signal at the site of DNA damage, as well as 
phosphorylation of the transducer kinase Chk1 (Liu et al., 2006). ATR is clearly important in 
the DNA damage response pathway and mutations in ATR have been associated with the 
congenital growth disorder Seckels syndrome. Unlike with ataxia telangiectasia patients, 
patients with Seckels syndrome display severe mental disabilities without displaying 
sensitivity to DNA damaging agents or a predisposition to cancer (O'Driscoll et al., 2004). 
Also, differing from studies with ATM, knockdown of ATR resulted in embryonic lethality 
in mice (De Klein et al., 2000). The embryonic lethality of ATR knockdown in mice 
indicates that ATR is an essential gene for viability in this organism. 
Chk1 and Chk2 represent the other two main transducer kinases that are required for 
cell cycle arrest in the response to DNA damage. Unlike ATM and ATR, Chk1 and Chk2 are 
structurally different but appear to have overlapping functions in the DNA damage response 
pathway (Bartek et al., 2001). The role of Chk1 and Chk2 is mainly focused on the relay of 
phosphorylation signals from the foci situated ATR and ATM to downstream effector 
proteins (Abraham, 2001). While both Chk1 and Chk2 are activated as part of the DNA 
damage response pathway, their basal expression and activation differ greatly. Chk1 is 
present in S phase and G2 phase, and though further induction of its activation has been 
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shown in response to DNA damage, it has also been shown in an active state in unperturbed 
cell cycles (Bartek and Lukas, 2003). Chk2 on the other hand, is stably expressed in an 
inactive form throughout the cell cycle, and it is activated in response to DSBs through 
phosphorylation mainly by ATM (Chaturvedi et al., 1999). Activation of Chk2 requires 
dimerization and autophosphorylation, whereas Chk1 does not require either of these for 
activation (Bartek and Lukas, 2003). It was originally thought that Chk1 was activated 
through ATR and Chk2 was activated through ATM, representing two different pathways. 
Studies showing “cross-talk” between the two pathways have demonstrated that the 
phosphorylation of Chk1 and Chk2 by ATR and ATM are not exclusive. ATM-independent 
activation of Chk2 has been shown (Hirao et al., 2002), along with ATM-dependent 
phosphorylation of Chk1 in response to ionizing radiation (Gatei et al., 2003). Along with 
direct activation by transducer kinases, the activation of Chk1 and Chk2 is also modulated by 
sensors and mediators such as 53BP1, BRCA1, and MDC1, which share a BRCT domain in 
common (Bartek and Lukas, 2003). Once active in the pathway, both Chk1 and Chk2 can 
phosphorylate p53 on Ser20, disrupting its association with its negative regulator Mdm2 
(mouse double minute 2) (Shieh et al., 2000). MdmX, which forms an active heterodimer 
with Mdm2, has also displayed phosphorylation by Chk2, leading to further inhibition of 
interaction between p53 and Mdm2/MdmX (Chen et al., 2005b). Both of these events lead to 
an accumulation of p53, which can then transactivate downstream proteins.  
1.1.4 Effectors 
Chk1 and Chk2 are occasionally categorized as effector kinases. While Chk1 and Chk2 
primarily act as transducers in the DNA damage checkpoint pathway, they help to regulate 
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proteins involved in DNA repair, replication fork maintenance, transcriptional regulation and 
apoptosis (Stracker et al., 2009). The regulation of these proteins is more characteristic of 
proteins in the effector category. Both Chk1 and Chk2 have been shown to target the Cdc25 
family of phosphatases (Cdc25A, B, and C), which are involved in cell cycle progression, 
both during normal division, and after recover from DNA damage (Boutros et al., 2006). The 
Cdc25 family of proteins normally dephosphorylate cyclin dependent kinases (Cdks) to 
regulate cell cycle progression, but when phosphorylated, their phosphatase activity is 
downregulated by direct inhibition, nuclear exclusion, ubiquitination, and degradation (Niida 
and Nakanishi, 2006). 
Another prominent effector protein is the tumour suppressor protein p53, which is an 
important part of the DNA damage checkpoint. It is known as a tumour suppressor protein 
because loss-of-function mutations in the p53 gene are present in greater than 50% of 
cancers. It is a transcription factor that can initiate DNA repair, cell-cycle arrest, senescence 
and apoptopsis in the checkpoint pathway, aiding the suppression of cancer (Vazquez et al., 
2008). In normally dividing cells, p53 levels are kept low by targeted nuclear export and 
degradation by its negative regulator Mdm2, although other research has shown that there 
may be other factors (MdmX, ARF, COP1, PirH2) which are also involved in the control of 
p53 ubiquitination and degradation (Brooks and Gu, 2006). In the event of DNA damage, 
p53 is phosphorylated by the signal transducers in the checkpoint pathway, which prevents 
its ubiquitin-mediated protein degradation (Helton and Chen, 2007). The regulation, 





Figure 1.3 p53 regulation and activation 
Under normal conditions, p53 is negatively regulated and kept at low levels through 
degradation. In the presence of DNA damage, p53 is activated, mainly through 
phosphorylation. This diagram is highlights the main pathways of p53 regulation and 
activation in mammalian models. Solid arrows represent protein interactions. Dotted arrows 
represent “cross-talk”. Purple Ps represent phosphorylation. Green Us represent 





1.2.1 Regulation  
p53 can be controlled in several ways but the main mode of regulation is through changes in 
protein stability. The levels of p53 protein are normally kept at low levels in the cell through 
proteasomal degradation. Mdm2, a well known negative regulator of p53, is one of the key 
proteins responsible for targeting p53 for degradation. Mdm2 is an E3 ubiquitin ligase that 
can ubiquitinate p53, targeting it for export from the nucleus and subsequent degradation by 
proteasomes (Michael and Oren, 2002). It was shown in 1997 to be highly specific for p53 
(Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997) and loss of Mdm2 in vivo can 
lead to p53-mediated apoptosis. Along with Mdm2, the related protein MdmX is also 
important for p53 regulation. Unlike Mdm2, MdmX is an essential negative regulator of p53 
(Marine and Jochemsen, 2005), though MdmX does not possess any E3-ligase ability. 
Instead, it regulates p53 through its interaction and binding with Mdm2. It has also been 
shown to repress the transcription factor functions of p53 (Marine and Jochemsen, 2005). 
Although Mdm2 is the main ubiquitin ligase for p53 regulation, other studies have shown the 
involvement of other ubiquitin ligases such as COP1 (Dornan et al., 2004), Pirh2 (Leng et 
al., 2003), and Arf-BP1 (Chen et al., 2005a) in the degradation of p53, displaying the 
complexity of p53 regulation. While these proteins are involved in the control of p53, their 
presence cannot compensate for loss of Mdm2 in vivo (Hock and Vousden, 2010). While 
ubiquitination is the main method of targeting p53 for degradation, it has also been shown 
that ubiquitination of p53 can be independent of degradation. The proteins Msl2 and Wwp1 
are able to ubiquitinate p53, localizing it to the cytoplasm, without targeting it for 
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degradation. It is hypothesized that these mechanisms of localization may be involved in the 
transcription-independent functions of p53, which require its localization to the cytoplasm 
(Kruse and Gu, 2009). 
While ubiquitination is the main method of p53 regulation, p53 can also be regulated 
by other other ubiquitin-like protein (UBL) modifications such as SUMOylation and 
NEDDylation. SUMOylation involves the modification of proteins through the addition of 
SUMO proteins (Small Ubiquitin-like Modifier), whereas NEDDylation involves the 
addition of the ubiquitin-like protein Nedd8. These UBL modifications also act on lysine 
residues at the carboxy terminal end of p53, similar to ubiquitination (Hock and Vousden, 
2010). Both SUMOylation and NEDDylation can be promoted by Mdm2, as well as several 
other proteins. For SUMOylation, the PIAS family (protein inhibitors of activated STAT) of 
SUMO E3 ligases has to been shown to target p53 for SUMOylation (Rytinki et al., 2009). 
SUMOylation of p53 results in reduced acetylation and reduced chromatin binding (Wu and 
Chiang, 2009), which is likely to inhibit the function of p53 as a transcription factor. 
SUMOylation mainly affects lysine 386 of human p53 and it has also been hypothesized that 
it can aid in the nuclear localization of p53 (Stehmeier and Muller, 2009). NEDDylation on 
the other hand, mainly affects lysines 320 and 321 of human p53. Aside from Mdm2, the F-
box protein FBXO11 can also NEDDylate p53 (Abida et al., 2007). NEDDylation of p53 
shows similar outcomes to SUMOylation, with decreased transcriptional activity, and 
inhibition of nuclear export (Xirodimas, 2007). Together, these results emphasize the 
importance of ubiquitination and of other UBL protein modifications which are crucial in the 




Since Mdm2 is an important regulator of p53, changes in Mdm2 itself are important for 
control of p53. Under normal conditions, Mdm2 forms either a homodimeric complex with 
itself, or a heterodimeric complex with the related protein MdmX (Linke et al., 2008). 
Though MdmX lacks E3 ligase activity, there is increasing evidence for the importance of 
the Mdm2/MdmX heterodimer as the more active regulator of p53 (Okamoto et al., 2005). 
Independently, both Mdm2 and MdmX have the ability to bind p53 and, despite their 
sequence homology, they carry out non-redundant roles in the negative regulation of p53. 
Since ubiquitin ligases play a large role in p53 regulation, the role of deubiquitinating 
proteins have also been examined. Certain proteins that function as deubiquitinating 
enzymes, such as HAUSP (Herpesvirus-associated ubiquitin-specific protease), can 
deubiquitinate both p53 and Mdm2, leading to stabilization of both proteins in a competitive 
feedback loop (Li et al., 2004). Mdm2 and MdmX can also be phosphorylated by ATM 
(Cheng and Chen, 2010), resulting in the inhibition of dimerization, as well as prevention of 
binding with p53. Chk1 and Chk2 are also able to phosphorylate MdmX, promoting its own 
inactivation and degradation (Chen et al., 2005b). Under conditions of genotoxic stress, 
Mdm2 can also act as a negative regulator of MdmX, targeting it for degradation through 
ubiquitination (Cheng and Chen, 2010). In addition to these mechanisms, there are other 
proteins that can interact with Mdm2 to regulate its activity. p14ARF (Khan et al., 2004), 
Numb (Colaluca et al., 2008), and Pin1 (Siepe and Jentsch, 2009), have all been shown to 




In addition to inhibiting negative regulators of p53, several protein kinases in the 
DNA damage checkpoint pathway are also able to stabilize and activate p53 through direct 
phosphorylation of its serine and threonine residues at several different sites, mainly located 
in the N-terminal region (Joerger and Fersht, 2008). ATM and ATR have both been shown to 
activate p53 through phosphorylation, mainly of Ser 15 (Abraham, 2001). Chk1 and Chk2 
have also been shown to phosphorylate p53 at several sites (Ou et al., 2005). These 
phosphorylation events are induced by DNA damage, leading to an activation of p53. 
Phosphorylation of p53 at certain sites also facilitates acetylation of p53 lysine residues, a 
result which is seen during genotoxic stress. It is hypothesized that the acetylation of p53 
inhibits its ubiquitination by Mdm2, due to competition for the same carboxy terminal 
residues. Phosphorylation of human p53 has been detected at 17 different serine (6, 9, 15, 20, 
33, 37, 46, 315, 376, 378, 392) and threonine (18, 55, 81, 150, 155) sites after DNA damage 
induced by irradiation, with 3 of these sites (Thr55, Ser376, Ser378) being constitutively 
phosphorylated (Bode and Dong, 2004). Of these sites, some are phosphorylated by multiple 
kinases, some of which can phosphorylate multiple sites, generating a complex network of 
regulation through phosphorylation. While research in p53 phosphorylation is mainly 
focused on phosphorylation as a consequence of DNA damage, one study has examined the 
phosphorylation of p53 at various stages throughout the cell cycle in untreated human 
fibroblasts (Buschmann et al., 2000). Their study revealed that p53 phosphorylation is 
dynamic, and that phosphorylation at several sites were transient events throughout the cell 
cycle of normal cells. Of the known sites of phosphorylation, Ser15 phosphorylation is one of 
the most frequently described and has been shown in response to genotoxic stress signals. 
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One of the main proteins responsible for phosphorylation of Ser15 of p53 is ATM (Khanna et 
al., 1998). 
The studies summarized here show that the modifications of p53 through 
ubiquitination, acetylation, and phosphorylation form a complicated map of interactions, 
which function together to regulate and activate p53. 
1.2.3 Mechanisms of action 
p53 is an important tumour suppressor protein that is involved in the transactivation of 
various proteins involved in cell cycle arrest, DNA repair, senescence, or apoptosis (Levine 
et al., 2006). Upon examining the structure of p53, several functional domains have been 
defined. The N-terminal regional contributes to the transactivation domain, followed by a 
proline-rich domain which is required for the mediation of apoptosis (Venot et al., 1998). 
The central core of the protein contains the DNA-binding domain and a tetramerization 
domain (Joerger and Fersht, 2008). This DNA-binding domain can target specific sequences 
of DNA for binding and the tetramerization domain regulates the oligomerization of p53 in 
the formation of its active state. The C-terminal region of the protein contains a regulatory 
domain which is thought to bind DNA in a non-specific manner. Once it has been activated 
through post translational modifications, p53 forms a tetramer and is able to act as a 
transcription factor for downstream proteins through its DNA-binding and transactivation 
domains (Joerger and Fersht, 2008). The first discovery of the sequence specific DNA-
binding activity of p53 was shown in 1991 (Bargonetti et al., 1991) (Kern et al., 1991), and 
the DNA consensus sequence of p53 response elements was published soon after in 1992 (El-
Deiry et al., 1992). The determination of the sequence specific DNA-binding activity of p53 
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was an important discovery in defining the importance of p53 in tumour suppression. Many 
tumor-associated p53 mutations exist in the DNA-binding domain (Olivier et al., 2002), 
indicating that the sequence specificity is of great importance in p53 function. When p53 is 
stabilized and activated, it can interact with the promoter region of target genes to regulate 
their rates of transcription. Since p53 is involved in the regulation of many genes, Riley et al. 
(2008) proposed a set of four experimental criteria in their study to find p53-response genes. 
The putative p53-response gene must contain a p53 response element, it must also show a 
p53-dependent upregulation or downregulation at the RNA and protein levels, it must 
demonstrate direct control of gene expression by p53 through a luciferase assay, and it must 
demonstrate direct binding of p53 to the p53 response element through chromatin 
immunoprecipitation (ChIP) (Riley et al., 2008). They were able to identify over 100 human 
genes that are candidates for regulation by p53, mostly involved in apoptosis, senescence, or 
cell-cycle arrest. These results further emphasize the importance of p53 in the control and 
maintenance of genome integrity and cell cycle regulation, through its transactivation of 
downstream genes.  
1.2.4 Non-mammalian models of p53 regulation 
While p53 has been studied to great depth in mammalian models, the research for p53 in 
non-mammalian models represents only a small portion of the published data on p53. From 
the data that is available for non-mammalian p53, similarities between p53 regulation, 
activation, and function can be found, though there is also strong evidence of unique 
mechanisms which differ from the mammalian models.  
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Studies on the Drosophila p53 orthologue have shown that like mammalian p53, it is 
able to bind specific regions of DNA and act as a transcriptional activator (Steller, 2000). 
These studies also demonstrated that p53 overexpression can induce apoptosis, and 
dominant-negative mutations can block IR-induced apoptosis (Steller, 2000). Despite these 
similarities, several key differences exist between Drosophila p53 and mammalian p53. As 
mentioned earlier, in mammalian models, Mdm2 is the key negative regulator of p53. 
However, in Drosophila, the essential residues for Mdm2 binding are not conserved in p53 
(Brodsky et al., 2004) and a homologue for Mdm2 has not been found (Rubin et al., 2000). 
Activation of p53 in Drosophila also appears to differ from established mammalian models. 
In a study of apoptotic pathways in Drosophila, it was found that, like mammalian p53, 
Drosophila p53 was responsible for the transactivation of many genes in the apoptotic 
pathway (Brodsky et al., 2004). However, the same study also showed that while p53 was 
necessary, it was activated without changing total p53 protein levels. This differs from 
mammalian models which usually display a several fold increase in p53 levels once it has 
been activated. Along with differences in Drosophila p53 regulation and activation, 
differences in p53 function have also been shown. Mammalian p53 is known to be involved 
in cell cycle arrest, DNA repair, and apoptosis, and while Drosophila p53 was shown to be 
involved in apoptosis, it does not seem to be involved with cell cycle arrest (Steller, 2000). 
Although these results are novel for p53, they are not unique to Drosophila, as other studies 
have shown similar findings in additional non-mammalian organisms. 
Like Drosophila p53, zebrafish p53 also displays similarities and differences to 
mammalian p53, though the differences are fewer. Unlike in Drosophila, a zebrafish Mdm2 
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protein has been found that has conserved functional domains and displays interaction with 
p53 (Thisse et al., 2000). The importance of the p53 DNA-binding domain is also apparent in 
zebrafish, as studies into mutations in the DNA-binding domain have shown that they result 
in higher susceptibility of these zebrafish to neuronal tumors (Berghmans et al., 2005b). 
While the mechanisms of zebrafish p53 activity appear very similar to mammalian p53, a 
study by Thisse et al. in 2000 showed that overexpression of Mdm2 in zebrafish embryos did 
not lead to spontaneous tumour formation, though similar studies in mouse models did 
display a high rate of tumour formation (Jones et al., 1998). 
In contrast to the results seen with zebrafish, studies of p53 in the medaka fish 
displayed several distinct differences in activation and function in comparison with 
mammalian p53. It has been noted that mutations in the p53 gene have rarely been found in 
naturally occurring or induced tumours in fish and studies of induced tumours in medaka fish 
have shown similar results, with no mutations found in p53 mutational hotspots of several 
induced tumours (Krause et al., 1997). This result differs greatly from the mammalian model, 
as mutations in p53 are found in many mammalian tumours. In terms of p53 activation, it has 
been shown that p53 transcript levels can be induced in mammalian cells after exposure to 
UV radiation, but this induction of p53 transcripts was absent in medaka based experiments 
(Chen et al., 2001). 
Comparable differences in p53 have also been found in several other non-mammalian 
models. Similar to the results discussed for drosophila and zebrafish, rainbow trout cells have 
shown a lack of p53 induction when exposed to agents that are known to induce p53 in 
mammalian models (Embry et al., 2006). Dosing with various chemotherapeutic agents 
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showed a lack of induction for rainbow trout p53, in comparison to the obvious increase seen 
in mammalian control cells (Embry et al., 2006). Similarly, a study in ayu showed a lack of 
total p53 induction under apoptotic conditions induced by aging related oxidative stress 
(Nagasaka et al., 2006). However, they did observe an induction of p53 phosphorylation on 
Ser15, an event which commonly accompanies total p53 induction in mammalian models 
(Canman et al., 1998). A study of urodele p53 generated similar results to those described in 
the ayu study. After treatment of urodele cells with UV, a lack of induction in p53 after 
treatment was seen, along with an induction of Ser15 phosphorylation (Villiard et al., 2007). 
This study also showed interesting results upon sequencing of urodele p53. In a comparison 
of urodele p53 and human p53, it was found that the urodele p53 had multiple amino acid 
differences that were found in human tumours. This result indicated that the urodele p53 was 
able to tolerate amino acid changes that are predicted to inactivate human p53. 
When viewing p53 from an evolutionary point of view, the differences in p53 
between the different animal models can be partially supported by the ancestry of p53. In a 
study of p53 ancestry, it was determined that the appearance of cancer was predated by 
primordial p53 genes, inferring that p53-like proteins were not originally selected for based 
on tumour suppressive properties (Lu et al., 2009). This change in function of p53 could 
explain the differences between mammalian models of p53 versus the non-mammalian 
models. Well known mechanisms of regulation, activation and function of mammalian p53 
may not be a result of ancestral p53 mechanisms, but rather represent newer developments in 
p53 evolution. Given the important role of p53 in tumour suppression and the high frequency 
of p53 mutations in human cancers, the current link between mammalian p53 and cancer is 
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indisputable, but this link may not be found in lower vertebrates. By examining the early 
mechanisms of p53 regulation, activation, and function, new insights into the evolution of 
p53 can be gained, possibly leading to potential uses in the development of novel cancer 
therapeutics. 
1.3 Aquatic toxicology 
1.3.1 Rainbow trout as a model organism 
Environmental toxicology in an important area of research that deals with the effects of toxic 
substances on the environment. These toxicants are usually released into the environment by 
human actions and can negatively affect the environment. For research into aquatic 
toxicology, teleost species are commonly used as model organisms. Due to a genome 
duplication event at the base of teleost radiation, the evolution of fish species was facilitated, 
leading to fish composing more than half of all vertebrate species (Furutani-Seiki and 
Wittbrodt, 2004). They are also useful due to their presence in most aquatic environments 
around the world, and their importance in the diet of diverse populations. Oncorhynchus 
mykiss (rainbow trout) in particular, is a commonly cultivated freshwater fish in North 
America and it is one of the best studied fish species due to its usefulness as a model 
organism for environmental carcinogenesis, toxicology, comparative immunology, 
physiology, and disease ecology (Thorgaard et al., 2002). It also has a high sequence 
availability, in terms of expressed sequence tags (ESTs), with Danio rerio (zebrafish) being 
the only fish species to have a higher availability than the rainbow trout (Govoroun et al., 
2006). In terms of aquatic toxicology research into the effects of toxicants, the use of 
rainbow trout as a model organism is also advantageous due to the large number of cell lines 
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available for use. Currently, a search of the American Type Culture Collection catalogue 
retrieves 5 rainbow trout derived cell lines (RTG-2, RTH-149, SOB-15, RTgill-W1, RTG-
P1), though these represent only a fraction of the total number of rainbow trout cell lines that 
have been available for research. A list of fish cell lines compiled in 1994 consisted of 125 
cell lines from 52 species of freshwater fish in 21 families, with 13 of those cell lines 
originating from rainbow trout (Fryer and Lannan, 1994). The use of cell lines can also be 
advantageous to whole fish studies in regards to constraints of experimental design. With cell 
lines, a large amount of data can be produced in a shorter amount of time with less resources, 
which is useful in generating initial discoveries that can then be examined in whole fish 
studies. For these reasons, the rainbow trout represents a great model organism for a variety 
of studies regarding the effects of environmental contaminants. 
1.3.2 Biomarkers 
Due to the constant increase of urban communities and industries, many aquatic 
environments are increasingly exposed to xenobiotics and other pollutants being released into 
the environment. Normally when assessing water quality, a number of physical, chemical, 
and biological parameters are experimentally assessed to generate a water quality index 
(WQI), which can be compared to existing guidelines (Boyacioglu, 2009). These parameters 
can be evaluated through environmental risk assessment (ERA), which attempts to determine 
the likely or actual adverse effects of pollutants on ecosystems using scientific methodologies 
(Depledge and Fossi, 1994). While many chemicals are not directly toxic to humans, they 
can have deleterious effects on the natural resources we rely on, emphasizing the importance 
of ERA in environmental analysis. Though the determination of water quality through 
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detection of environmental levels of pollutants is useful, this does not provide a full picture 
of their effects on the environment, as various toxicants can have a combined consequence 
that is greater than the sum of their individual effects (Calabrese, 1995). The deleterious 
effects of long term exposure to compounding pollutants may not be apparent initially in the 
endogenous fish population, and by the time the effects manifest, it may be too late to reverse 
the damage. It is due to these concerns that recent research has highlighted the use of 
biomarkers in the assessment of changes within a biological system. Biomarkers can be 
defined as measurements in body fluids, cells, or tissues, which can indicate biochemical or 
cellular changes (NRC, Committee on Biological Markers, 1987). In terms of toxicology, 
they can also be defined as xenobiotically induced changes in cellular or biochemical 
components or processes, structures or functions, which can infer exposure and be used to 
assess the biological effects (Shugart, 1992). Ideally, a biomarker should meet several 
requirements. The method of collection should be simple, reliable and ethical; it should be 
indicative of a specific type of exposure; and it should detect a reversible subclinical change 
(Gil and Pla, 2001).While biomarkers can be used to assess exposure between an organism 
and potential hazards in any environment, a good proportion of the research has been 
aquatically based, focusing on fish studies. Both transcript levels and protein levels have 
been used as environmental biomarkers in a variety of fish studies for possible use in 
diagnostic tools (Tom and Auslander, 2005). Metallothioneins (MT), a family of cysteine-
rich proteins, has been examined for biomarker use due to its metal binding capacity. They 
have been studied in many aquatic vertebrates and have shown clear induction in several of 
these marine species after exposure to metal contaminants (Monserrat et al., 2007). Another 
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well studied biomarker for environmental contamination in aquatic environments is 
cytochrome P450. It has shown sensitive dose dependent induction in many marine species 
after exposure to contaminants (Bucheli and Fent, 1995). Currently, the search for new 
biomarkers has involved the use of new technology for large screening tests in an effort to 
identify possible candidates for further testing. Due to the use of tissue microarrays, many 
potential biomarkers have been found for many areas of research (Giltnane and Rimm, 
2004). Many of these studies are clinically based, but the use of tissue microarrays for 
screening could be extrapolated to aquatic biomarker studies as well. Though the use of 
biomarkers is not a recent development, the increasing use of biomarkers in aquatic 
toxicology requires increased research into characterizing DNA damage response pathways 
in fish, as these pathways may differ from the expected mammalian mechanisms. 
1.4 Research Objectives 
The main purpose of this thesis was to generate a rainbow trout specific p53 antibody for use 
in rainbow trout cell line based studies to determine the potential biomarker application of 
p53. This thesis is a small component of a larger project, with the goal of generating a 




Materials and Methods 
2.1 Expression construct 
Rainbow trout p53 was cloned from rainbow trout gill cell line (RTgill-W1) cDNA using 
forward (5’ GACTTCTCGAGCTGGCGGAGAACGTGTCTCTTC) and reverse primers (5’ 
GGACTTAAGCTTCACTCCGAAGTCCCGTTTGGC) with XhoI and HindIII restriction 
sites respectively. These primers are targeted to amplify a 1125bp region of the rainbow trout 
p53 cDNA sequence (Caron de Fromentel et al., 1992) that encodes amino acids 4-378 of the 
396 aa long protein. The amplified fragment was gel purified and then inserted into a pRSET 
A expression vector (Invitrogen) through digestion with XhoI and HindIII restriction 
enzymes. The ligation reaction was the performed using T4 DNA ligase (Promega) which 
results in the expression of a fusion protein with a polyhistindine tag and an Xpress epitope at 
the N-terminal end of the recombinant protein. This construct, pRSETA-RTp53, was then 
transformed into competent (DE3)pLysS E. coli cells (Promega) for inducible expression of 
recombinant rainbow trout p53 according to the manufacturer suggested protocol. The 
construct was also sequenced to confirm that the insert was in frame. The sequencing 
revealed a point mutation at base 1096, which causes an amino acid substitution of a cysteine 
to an arginine. This mutation is located in a non-conserved region of the gene. 
2.2 Protein expression and purification 
Cells transformed with the expression construct were grown in liquid SOB media 
supplemented with 100μg/ml ampicillin, shaking at 250 rpm at 37°C to an optical density of 
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0.4-0.6, before a 4 hour induction of recombinant protein expression with IPTG (in a final 
concentration of 1mM). After the 4 hour induction, the E. coli cells were harvested by 
centrifugation at 5 000 x g for 10 min and were lysed overnight at room temperature with a 
denaturing 8M urea buffer (100mM NaH2PO4, 10mM Tris-HCl, 8M urea, pH 8). The lysate 
was then centrifuged at 10 000 x g for 6 mins at 4°C before saving the supernatant and 
discarding the pellet. To isolate the recombinant p53 from the supernatant, affinity 
chromatography was performed in an econo-column (Bio-Rad) filled with Ni-NTA resin 
(Qiagen). This resin was allowed to bind the polyhistidine tag at the N-terminus of the 
recombinant protein during a 2 hour incubation with the lysate on a rotator at 4°C. After 
incubation, the flowthrough was discarded. The protein was then refolded on the column 
using a decreasing gradient of urea (6M-0M) before eluting in its native form with a 250mM 
imidazole elution buffer in 8 elution fractions of 1mL each. A 10µL sample of each fraction 
was then run on a 12% SDS-PAGE gel and analyzed by Coomassie blue staining to 
determine the fraction with the highest protein yield. This elution fraction (~1mL) was then 
dialyzed overnight at 4°C into 200x buffer volume of 1x PBS. The dialyzed protein sample 
was then analyzed through SDS-PAGE and Coomassie blue staining once again to verify that 
the protein of interest was still intact and present in the sample. A Bradford protein assay was 
then performed to determine protein yield of the samples. The dialyzed recombinant protein 
sample fractions were then combined and stored at -20°C in 1ml aliquots of 0.7mg/ml for 
future use as immunogen injections in rabbits. 
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2.3 Production of polyclonal antibodies to recombinant proteins 
The purified protein was injected into 2 rabbits over a period of three months to produce a 
high titre of antibodies to the purified protein. Rabbits were immunized subcutaneously with 
200µL of recombinant p53 (~0.7mg/mL) mixed with 200µL of Freund’s complete adjuvant 
(Sigma), at four different injection sites. The rabbits were then given booster shots of a 
similar emulsion (but with Freund’s incomplete adjuvant) at three week intervals, for three 
additional boosts. Blood samples were obtained before each boost through the marginal ear 
vein of each rabbit. To separate the serum from the blood, samples were left at room 
temperature for 2 h and then overnight at 4°C to allow the blood to clot. Samples were then 
centrifuged at 5 000 x g for 10 min at 4°C to pellet the blood cells, and the serum was 
collected and assessed for antibody titre through ELISA analysis with purified recombinant 
p53 (described below). At the end of the twelfth week, the rabbits were exanguinated by 
carotid cannulation for final collection of total blood.  
2.4 Determination of antibody titre through Enzyme-Linked Immunosorbent 
Assay (ELISA) 
Before each boost, and after the final bleed, serum antibody titers were determined through 
ELISA. Microtiter plates were coated with 100µl of 10µg/ml purified recombinant p53 
protein diluted in coating buffer (15mM Na2CO3, 34mM NaHCO3, 0.02% NaN3, pH 9.3) and 
incubated for 2 h at room temperature. The wells were then blocked with 300μl of blocking 
buffer (1% BSA and 0.02% NaN3 in 1X TBST) for 2 h at room temperature. The collected 
serum was then serially diluted and added to the wells in replicates at 100μl per well in 
blocking buffer and incubated for 2 h at room temperature. An alkaline phosphatase 
 
 30 
conjugated anti-rabbit IgG antibody (Bio-Rad) was diluted 1:5000 in blocking buffer and 
added at 100μl per well and incubated for 2 h at room temperature. The plates were then 
detected with SigmaFAST p-Nitrophenyl phosphate tablets (Sigma) according to the 
manufacturer suggested protocol, and incubated for 30 min in the dark before stopping the 
reaction with 3N NaOH by adding 50μl directly to the the wells. Absorbance was measured 
at 405 nm using a microplate reader (VERSAmax microplate reader, Molecular Devices). 
Readings were obtained after background correction through the SOFTmax PRO 2.6.1 
program. 
2.5 SulfoLink purification of RTp53 antibody from serum 
Antibodies specific to recombinant rainbow trout p53 were purified from crude serum with a 
SulfoLink Immobilization Kit for Proteins (Pierce). The SulfoLink column was generated by 
binding recombinant rainbow trout p53 to the resin to produce an affinity column specific for 
antibodies against this protein. This was done according to the manufacturer’s suggested 
protocol with minor changes. To prepare the protein for coupling, the protein was reduced 
with 2-mercaptoethylamine (2-MEA) and run through the provided desalting column to 
remove remaining 2-MEA. The recombinant p53 had a concentration of 0.7mg/ml and 1ml 
of this was used directly in the reducing reaction before running through the desalting 
column. All steps for binding of the recombinant protein to the SulfoLink column were done 
according to the manufacturer’s protocol. For affinity purification of p53 specific antibodies 
from the serum, 2ml of pure serum was used for each run. Each wash was performed the 
maximum amount of suggested times. The bound antibodies were then eluted into 4 aliquots, 
1mL at a time with elution buffer. These aliquots were then evaluated using a Bradford 
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protein assay to determine the aliquots with the highest concentration of antibody. These 
aliquots were then stored for future use and the SulfoLink column was prepared for storage. 
A prepared SulfoLink column can be reused for multiple purifications when properly stored 
according to the manufacturer’s suggested protocol. 
2.6 Cell culture and treatment regimes 
The RTbrain-W1 and RTgill-W1 cell lines were obtained from Dr. Niels C. Bols (University 
of Waterloo). The RTbrain-W1 cell line was derived from rainbow trout brain glial cells. The 
RTgill-W1 cell line was derived from rainbow trout gill epithelium and is available from the 
American Type Culture Collection (ATCC CRL 2523). The cell lines were maintained in 
75cm2 flasks at 18°C in  L-15 media (Sigma) supplemented with 15% FBS (Sigma) and 10% 
FBS respectively. Media was also supplemented with 1% penicillin-streptomycin solution 
(Sigma) to inhibit bacterial growth. For dosing studies, cells were seeded in 25cm2 flasks at 
either 1.5 x 106 (RTbrain-W1) or 3 x 106 (RTgill-W1) cells per flask, 24 hours prior to 
treatment. Bleomycin (Calbiochem), hydroxyurea (HU)(Sigma), and methyl 
methanesulfonate (MMS)(Sigma) were all readily dissolved in media and were added to the 
cells at the concentrations indicated for each experiment. At the time of dosing, fresh media 
was also added to untreated control flasks to mimic dosing. Flasks were then incubated in the 
dark at room temperature for the indicated time points of exposure. 
2.7 Protein extraction from tissue culture 
Cells were harvested by scraping the cells with a cell scraper and pelleted through 
centrifugation at 1000 x g before lysis with 50µL of RIPA lysis buffer (50mM Tris-Hcl pH 
8.0, 150 mM sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium 
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dodecyl sulphate), with 1x Complete Mini Protease Inhibitor Cocktail Tablets (Roche) and 
1x PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche) per 25cm2 flask of confluent 
cells. Lysate was then spun at 16 000 x g for 10 min to remove cell debris before determining 
protein concentration using a Bradford reagent (Bio-Rad) according to the manufacturer’s 
suggested protocol. 
2.8 Protein extraction from tissues 
Rainbow trout were obtained from Alma Research Station (in association with the University 
of Guelph) and were acclimated for at least two weeks at the University of Waterloo prior to 
any experimentation in 200 L aerated tanks with constant water flow at 13°C. Fish were 
maintained on a 12 hr light:12 hr dark photoperiod. Organs were harvested from the rainbow 
trout and frozen on dry ice before storage at -80°C. Lysates were prepared through 
homogenization and sonication of frozen tissues in 50mM Tris-HCl buffer (pH 7.5) plus 1x 
Complete Mini Protease Inihibitor Cocktail Tablets (Roche). Lysates were centrifuged at 16 
000 x g for 10 min to remove insoluble proteins. The supernatant was retained and protein 
concentrations were determined through Bradford protein assay (Bio-Rad) according to the 
manufacturer suggested protocol. 
2.9 Western blotting 
Protein extracts were run at 20μg per sample (unless otherwise specified) on 12% SDS-
PAGE gels and transferred to 0.2μM nitrocellulose membranes (Bio-Rad). Membranes were 
blocked in 5% dry milk in 1X TBST (50mM Tris-HCl pH 7.4, 150mM NaCl, 0.1% Tween 
20) for 1 h at room temperature. The membranes were then probed with the appropriate 
primary antibodies at the following concentrations: anti-Xpress antibody (Invitrogen) 1:5000, 
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p53 (FL-393) antibody (Santa Cruz Biotech) 1:200, purified rainbow trout p53 antibody 
1:200, Phospho-p53(Ser9) antibody (Cell Signalling) 1:1000, Phospho-p53(Ser293) antibody 
(Cell Signalling) 1:1000, p-Histone H2A.X (Ser139) antibody (Santa Cruz Biotech) 1:200, 
Phospho-(Ser/Thr) ATM/ATR Substrate Antibody (Cell Signalling) 1:1000, Monoclonal 
anti-actin-Cy3 (Sigma) 1:1000. For all primary antibodies except the anti-actin-cy3, 
membranes were probed with either an Alexa Fluor 488 goat anti-rabbit IgG secondary 
antibody (1:3000) or an anti-rabbit-HRP secondary antibody (Bio-Rad) 1:3000, before 
detection with ECL Plus detection kit (Amersham) as per the manufacturer’s suggested 
protocol. The anti-actin-Cy3 did not require a secondary antibody for detection due to its 
conjugation to a fluorescent Cy3 tag. For the phospho specific antibodies, incubations were 
done in 5% BSA in 1X TBST rocking overnight at 4°C. All other antibodies were incubated 
for an hour at room temperature in 5% dry milk in 1X TBST. The membranes were then 
imaged using a Typhoon 9400 Variable Image Scanner (GE Healthcare Life Sciences). 
2.10 Cell proliferation assay 
RTbrain-W1 and RTgill-W1 cells are plated into 24 well plates at a density of 0.6 x 105 cell 
per well or 1.2 x 105 cells per well respectively, 24hr prior to treatment. The media and 
incubation conditions are the standard conditioned outlined above for cell culture and 
treatment regimes. After allowing cells to attach for 24hr, the cells were then dosed for the 
specified concentrations and incubation times. At each time point specified, cells are 
trypsinized and collected for cell counting using a Coulter Counter Z2 (Beckman Coulter), 




Production of a rainbow trout specific polyclonal p53 antibody 
3.1 Introduction 
The DNA damage checkpoint is an important part of cell cycle regulation.  When cells are 
exposed to agents such as reactive oxygen species, UV radiation, and environmental 
pollutants, DNA within the cells can be damaged. The various types of damage caused to the 
DNA signals the DNA damage checkpoint response. This initiates pathways that lead to cell 
cycle arrest, DNA repair, or apoptosis (Niida and Nakanishi, 2006). Different pathways are 
initiated, depending on the type of DNA damage, but there are 4 main types of checkpoint 
proteins: sensors, transducers, mediators, and effectors (Houtgraaf et al., 2006). p53 is a main 
effector in the pathway and plays an important role as a tumour suppressor. 
The rainbow trout has been suggested as a good candidate for a model organism of 
aquatic environmental carcinogenesis due to its sensitivity to an array of human carcinogens 
(Bailey et al., 1996), low spontaneous tumour incidence and similar gene expression to 
mammalian hepatocarcinoma models (Williams et al., 2008). There are also a variety of 
rainbow trout cell lines available (Fryer and Lannan, 1994) for use in in vitro studies of DNA 
damage. 
Biomarker-based research is increasingly being used in the area of environmental 
carcinogenesis for the development of new tools and methods for early detection of potential 
disease-related changes in the cell (Kyrtopoulos, 2006). For aquatic studies, fish biomarkers 
of genotoxic damage are a valuable part of environmental risk assessment (ERA) of aquatic 
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ecosystems and environmental pollutants (van der Oost et al., 2003). Changes in gene 
expression caused by DNA damage can be used to determine the effects of pollutants in the 
environment (Liyan et al., 2005). RNA transcripts and proteins are gaining use as 
environmental biomarkers in the development of detection tools for changes caused by 
environmental contaminants (Tom and Auslander, 2005). In a recent study from the Duncker, 
Dixon, and Bols labs, rainbow trout transcript and protein levels for Chk2 were determined in 
tissue and cell line samples respectively, for potential biomarker use (Steinmoeller et al., 
2008). Another checkpoint protein, fish p53, has also been suggested as a possible biomarker 
for genotoxins in aquatic environments (Bhaskaran et al., 1999). A variety of fish p53 genes 
have been sequenced, including that of rainbow trout (Caron de Fromentel et al., 1992). 
Sequence data is useful in determining the degree of conservation between species, which 
can be used to infer functional similarities. Also, given the important role p53 plays in the 
checkpoint pathway, and the presence of its mutated form in many cancers, extensive studies 
have been published concerning the mechanisms and pathways of p53 (Vousden and Lane, 
2007). 
To evaluate the usefulness of p53 as a biomarker of DNA damage in rainbow trout, a 
polyclonal antibody to rainbow trout p53 was generated as described below. The potential 
applications of this antibody were investigated and outlined in Chapter 4. This antibody 
could be used in combination with other rainbow trout specific checkpoint protein antibodies 
to generate an ELISA or western blot based checkpoint biomarker assay for use in 
environmental testing. This method would represent a quick and efficient method of testing 
the biological effects of environmental pollutants on rainbow trout. To generate the assay, 
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rainbow trout specific antibodies will be generated against an array of checkpoint proteins to 
be used as biomarkers. These antibodies will be provided as part of a kit to be used for 
sensitive and specific detection of changes in gene expression caused by DNA damage.  
3.2 Results 
3.2.1 Preparation of rainbow trout p53 immunogen 
Catherine Tee, a previous member of the Duncker lab, cloned rainbow trout p53 from RTgill-
W1 cDNA using primers which amplified a 1125 base pair region of rainbow trout p53 
cDNA, coding for amino acids 4-378 of the 396 aa protein. An expression construct was then 
generated using the pRSET A expression vector system (Invitrogen). Sequencing of this 
construct, pRSETA-RTp53, revealed the presence of one point mutation at base 1096, 
causing an amino acid substitution from a cysteine to an arginine. This mutation is located in 
a non-conserved region of the gene and was determined to be acceptable for the purposes of 
antibody generation. The construct was then transformed into competent BL21 (DE3) pLySS  
E. coli cells. From this point, the recombinant protein was purified using a modified method 
of affinity purification with nickel resin (Qiagen) as described in Chapter 2. Figure 3.1 shows 
a Coomassie stain of the elution fractions that were obtained. The recombinant p53 has a 
theoretical molecular weight of 48 kDa based on protein sequence. This is slightly heavier 
than the theoretical molecular weight of 44 kDa for endogenous rainbow trout p53, which is 
expected, due to the addition of an Xpress epitope tag and a polyhistidine tag in the 
recombinant p53. The lone band at the top of the gel in all elution fractions appears at a 




Figure 3.1 Coomassie staining of recombinant protein elution fractions 
Elution fractions were collected in 1mL aliquots and 10µL of each fraction was run on a 12% 
SDS-PAGE gel before Coomassie staining to determine the fraction with the highest 
concentration of the protein of interest (indicated by the arrow).The molecular weights of the 
marker bands are indicated in kDa to the left of the image (Fermentas). The elution fractions 
are labelled E1-E8 in order of elution. The last lane (D2) is 10µL of elution fraction 2 after 
dialysis, showing that the protein of interest is retained in the dialyzed fraction. Background 







migration properties of p53. Human p53 has a theoretical molecular weight of around 43 
kDa, though it runs on a gel at around 53 kDa. This has also been observed in p53 proteins of 
other species and is thought to be due to a high number of proline residues in the protein 
(Oren, 1985; Soussi and May, 1996). Lane D2 shows that the protein is retained after dialysis 
in 1x PBS. There are several background bands visible in the high concentration fractions but 
these may be degradation products from the recombinant protein, due to the many steps 
during purification. Another possibility is the presence of histidine rich regions in other 
proteins, which could be binding to the affinity resin.  
To confirm that the protein in the Coomassie stain is the recombinant protein of interest, a 
western blot was done, detecting for the N-terminal Xpress epitope of the recombinant 
protein (Figure 3.2), using an anti-Xpress antibody (Invitrogen). From the Coomassie stain in 
Figure 3.1, the background bands are visible, but they are absent from the western blot. This 
indicates that the bands do not contain the XpressTM epitope, but it is still possible that they 
are degradation products of the original protein.      
To further confirm that the purified protein is recombinant p53, a commercial anti-
human p53 antibody (Santa Cruz) was used for western blot detection of the recombinant 
protein. In addition, human and rainbow trout cell lysate samples were used to determine the 
specificity of the antibody to endogenous human and rainbow trout p53. In Figure 3.3, 
maximum sample volume was loaded per well to facilitate detection of p53. The recombinant 
protein was run with human positive controls (HEK 293 T, HT-29) and various rainbow trout 
lysates to test specificity. HEK 293 T (human embryonic kidney cell line) lysates do not 




Figure 3.2 Detection of Xpress epitope in elution fractions. 
Western blot showing clear detection of the Xpress epitope in the elution fraction, confirming 
that the prominent band indicated by the arrow is the recombinant protein. Elution fractions 
were loaded at 10µL per well in a 12% SDS-PAGE gel. The molecular weights of the marker 
bands are indicated in kDa to the left of the image (Fermentas). The elution fractions are 
labelled E1-E8 in chronological order. The last lane (D2) is 10µL of elution fraction 2 after 
dialysis, showing that the Xpress epitope tagged recombinant protein is retained in the 
dialyzed fraction. The bands appearing beneath the prominent band are probably degraded 
forms of the protein. The Xpress epitope was detected using a primary antibody specific for 
the peptide sequence of the epitope (Invitrogen). An Alexa Fluor 488 goat anti-rabbit IgG 






Figure 3.3 Western blot of recombinant protein and various lysates detected with a 
human p53 antibody. 
Western blot showing detection of p53 in various samples using an antibody specific for 
human p53. Recombinant protein was loaded at 10µL and protein lysates were loaded at 
maximum volume (30µL) per well in a 12% SDS-PAGE gel. The molecular weights of the 
marker bands are indicated in kDa to the left of the image (Fermentas). The last lane is the 
recombinant protein, which is clearly detected by the p53 antibody, confirming that our 
recombinant protein is p53. The human and rainbow trout lysates were run to assess antibody 
specificity. Bands are detected for p53 in each sample except HEK-293T but the detection is 
not always clear. Ponceau S staining is provided as a loading control. p53 was detected using 
a polyclonal antibody to human p53 (Santa Cruz Biotech). An Alexa Fluor 488 goat anti-
rabbit IgG secondary antibody was used for fluorescent detection (Invitrogen). 
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has been previously shown that p53 basal levels can be detected on a western blot of HEK-
293 cell lysates (Evdokiou et al., 1999). This difference in detection could be due to the use 
of different commercial p53 antibodies, protein concentrations, and detection method. In 
contrast, the HT-29 (colon cancer cell line), does show a clear band between ~40 kDa, which 
is lower than expected for human p53. However, this result is consistent with previous 
literature that has shown the detection of p53 in HT-29 cell lysates (O'Connor, 1997). For the 
rainbow trout cell lines, RTL-W1 (liver cell line) was selected because p53 was detected by 
western in a previous study using the same commercial anti-human p53 antibody (Embry et 
al., 2006). The RTgill-W1 and RTbrain-W1 cell lines were chosen based on their anticipated 
use for the study outlined in Chapter 4, as well as their use in a previous study which 
determined Chk2 protein levels in these cell lines (Steinmoeller et al., 2008). There are 
detectable bands in the rainbow trout samples that are visible at the same level as the 
recombinant p53 band, but they are less distinct. This provided further evidence that the 
purified recombinant protein is indeed rainbow trout p53, since it has similar migration for 
SDS-PAGE as endogenous rainbow trout p53 and is easily detected by the human polyclonal 
antibody. This result also validates the need for a rainbow trout specific antibody for the 
detection of p53, as the detection from the rainbow trout samples was less than ideal. 
3.2.2 Analysis of anti-serum quality 
Once the quality of the purified protein had been checked, it was used for polyclonal 
antibody production in rabbits. Rabbits were immunized with aliquots of the purified protein 
over a period of 3 months. To monitor the production of antibodies, serum was tested before 





Figure 3.4 ELISA of serum samples from Rabbit 1 
Serum samples were taken from rabbit 1 before the initial immunization and before each 
booster shot. The serum from the final bleed was also tested. The ELISA shows that a high 




Figure 3.5 ELISA of serum samples from Rabbit 2 
Serum samples were taken from rabbit 2 before the initial immunization and before each 
booster shot. The serum from the final bleed was also tested. The ELISA shows that a high 










antibodies was being produced to the recombinant protein in both rabbits starting before the 
second boost (Figure 3.4 and Figure 3.5). 
When the final bleed serum was obtained, it was tested for specificity by western 
blotting. The pre-immune serum from each rabbit was also tested to determine if any initial 
background binding was present before immunization. Figure 3.6 shows that rabbit 1 
displayed higher initial background binding of pre-immune serum in comparison to the 
serum of rabbit 2. The background binding also seemed to be stronger for proteins around the 
size of p53. It was also determined that the final bleed serum from both rabbits produced a 
high amount of background binding (data not shown). To reduce this background, the serum 
was purified using a SulfoLink column as described in Chapter 2. The purified antibody was 
then compared to the final bleed serum (Figure 3.7). Serum from rabbit 2 was chosen for 
purification based on the lower amount of initial background in the pre-immune detection. 
Figure 3.7 shows that the SulfoLink purified antibody detects a clean band for p53, though 
some background binding is still present. 
3.2.3 Detection of rainbow trout p53 in cell lines and tissues 
The purified antibody was then tested for specificity in basal expression panels of various 
rainbow trout cell lines (Figure 3.8) and tissues (Figure 3.9). From these panels, it can be 
seen that p53 expression varies between tissue type and cell line type. For the cell line panel, 
the human antibody does not seem to be detecting p53 in all samples. Only the RTgut-GC 
sample shows a clear detection of the p53 at the correct size. The SulfoLink purified antibody 
shows clear detection of p53 bands, indicating that it is highly specific for p53 in rainbow 





Figure 3.6 Western blot of RTbrain-W1 and RTgill-W1 lysates using pre-immune 
serum. 
Western blots using pre-immune serum as primary antibody for detection (1:200). Proteins 
were loaded at 20 µg per well in a 12% SDS-PAGE gel. The molecular weights of the 
marker bands are indicated in kDa to the left of the image (Fermentas). Rabbit 1 shows a 
higher amount of cross reactivity in the pre-immune serum than Rabbit 2. A goat anti-rabbit 





Figure 3.7 Western blot of RTbrain-W1 and RTgill-W1 lysates showing specificity of 
the SulfoLink purified antibody. 
Western blots using either pre-immune serum, final bleed serum, or SulfoLink purified 
antibody as primary antibodies for detection (1:200). Proteins were loaded at 20µg per well 
in a 12% SDS-PAGE gel. The molecular weights of the marker bands are indicated in kDa to 
the left of the image (Fermentas). Serum from rabbit 2 was chosen for purification due to the 
lower background reactivity of the pre-immune serum. The SulfoLink purified antibody 
shows a clear detection of the p53 band, with most of the background binding from the final 





Figure 3.8 Panel of rainbow trout cell line samples detected for p53, comparing anti-
rainbow trout and anti-human antibodies. 
Western blots using either an anti-human p53 antibody (Santa Cruz Biotech) or the 
SulfoLink purified antibody, specific for rainbow trout p53. Proteins were loaded at 20µg per 
well in a 12% SDS-PAGE gel. Ponceau S staining is provided as loading controls. The 
samples represent cell lines derived from the following tissues: brain, gill, gonad, gut, liver, 
spleen. RTplasma is part of the panel though it is not a cell line. A goat anti-rabbit IgG HRP 




Figure 3.9 Panel of rainbow trout tissue samples detected for p53, comparing anti-
rainbow trout and anti-human antibodies 
Western blots using either an anti-human p53 antibody (Santa Cruz Biotech) or the 
SulfoLink purified antibody, specific for rainbow trout p53. Proteins were loaded at 20µg per 
well in a 12% SDS-PAGE gel. Ponceau S staining is provided as loading controls. A goat 
anti-rabbit IgG HRP conjugated secondary was used for detection (Bio-Rad).These results 
are representative of samples from three fish. 
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tissue panel, the detection of p53 with both antibodies shows a clear band for the first four 
tissues. For the spleen sample, a band is only detected with the human antibody. The 
SulfoLink purified antibody also shows a higher degree of background binding that is not 
seen in the cell line panel. 
3.3 Discussion  
In this study, I aimed to generate a polyclonal antibody that is specific for rainbow trout p53. 
This antibody would be used in conjunction with other rainbow trout checkpoint antibodies 
(that are currently being developed) to generate a biomarker assay for environmental 
toxicology by detecting DNA damage caused by environmental toxins. Currently, a 
commonly used technique for assessing DNA damage in the cell is through the comet assay 
(single cell microgel electrophoresis). Cells are embedded in agarose and lysed, before gel 
electrophoresis in alkaline conditions. The amount of DNA damage is assessed through 
fluorescence microscopy to determine the extent of DNA migration from the core of intact 
DNA (Singh et al., 1988), forming a comet-like appearance. Unfortunately, this method 
cannot be used as a standard bio-indicator in aquatic environments due to lack of 
standardization of methods and measurements of DNA damage (Lee and Steinert, 2003). By 
generating an ELISA based assay, analysis of results will be more absolute, based on 
comparisons with a given standard. 
To generate antibodies specific to rainbow trout p53, the recombinant p53 had to be 
purified from the bacterial host cells in a form that is acceptable for use as an immunogen. 
Purification of recombinant p53 from the BL21(DE3)pLysS E. coli was initially attempted 
using affinity chromatography with Ni-NTA agarose resin (Qiagen) and the manufacturer’s 
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denaturing purification protocol for cell lysis with 8M urea. Unfortunately, the purified 
protein from this method aggregated and formed a precipitate when the solvent (urea) was 
removed by dialysis into 1x PBS in preparation for injections. Previous research has 
documented that pure p53 protein can oligomerize and precipitate at high concentrations due 
to the oligomerization domain of p53 (Chalkley et al., 1994). It is also possible that in the 
fully denatured state, hydrophobic regions become accessible and form aggregates with the 
other denatured p53 proteins. The manufacturer’s suggested method of native purification 
was also attempted but Coomassie staining of the elution samples on a 12% SDS-PAGE gel 
showed that p53 protein yield was extremely low, possibly due to incomplete lysis of the 
cells. After sonication of the E. coli cells, a large pellet was still present after lysis, more so 
than with the denaturing method, indicating the presence of intact cells with the cell debris. 
To circumvent these issues, a modified method of affinity purification was created. Cells 
were lysed using the denaturing method with 8M urea buffer and incubated with the affinity 
resin for protein binding. The protein was then refolded on the column using a decreasing 
gradient of urea (6M-0M), before elution with a 250mM imidazole buffer and dialysis into 
1x PBS. This method was an optimal balance between quality and quantity of protein 
necessary for use in antibody production. Different antibodies were then used to confirm that 
the protein in the elution fractions was actually Xpress epitope tagged p53 (Figure 3.2 and 
Figure 3.3). 
Throughout the process of immunization, the serum of the rabbits was monitored for 
antibody titre through ELISA. The serum from both rabbits showed high reactivity to 
recombinant p53, even before the second boost (Figure 3.4 and Figure 3.5). Oddly, for both 
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ELISAs, there seemed to be an increase in reactivity, relative to the undiluted serum, as the 
dilution of the serum increased to 100. This could possibly be due problems with the 
preparation of the plates or interference of antibody binding from other substances in the 
serum. In either case, the ELISAs showed a definite increase in reactivity of serums to the 
purified recombinant p53 protein, relative to the pre-immune controls. This indicated that the 
immunization of the rabbits was working in generating antibodies to the recombinant p53 
protein. 
To determine the specificity of the final bleed anti-serum, western blots were 
performed. When using the pre-immune serum as the primary antibody, there seemed to be a 
higher amount of background reactivity in rabbit 1 (Figure 3.6). The final bleed serum from 
both rabbits showed a high amount of background binding in the initial detection, indicating 
the need for purification of the antibody from the serum. The serum from rabbit 2 was chosen 
for purification, as there was less initial background reactivity in the pre-immune serum. 
Since the banding pattern of detection with the pre-immune serum of rabbit 1 appeared 
around the size of p53, it would be harder to determine the specificity of the serum after 
purification due to lack of differentiation between initial background and final p53 detection. 
In Figure 3.7, a western blot with the purified serum shows that the background binding is 
greatly decreased and the p53 band can be clearly seen. There are still background bands 
present but these may represent detection of oligomers of p53 or possibly isoforms of p53.  
In terms of sample specificity, it can be seen that the SulfoLink purified antibody is 
better for detection of p53 in rainbow trout cell lines versus detection of p53 in rainbow trout 
tissues (Figure 3.8 and Figure 3.9). The detection in tissues shows a higher degree of 
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background binding. This is possibly due to the fact that cell lines are generated from one 
cell type, whereas tissues samples are a mass of various cell types, leading to more non-
specific binding of the antibody. For the cell lines, the SulfoLink purified antibody appears to 
detect p53 consistently, whereas the human p53 antibody does not. In using the human p53 
antibody, it has shown inconsistency in p53 detection, depending on the quality of the 
particular lot of antibody. 
Upon detection of p53 in various cell lines and tissues, a variability in basal protein 
levels can be seen. Normally, p53 is kept at a low level in mammalian cells until a 
checkpoint is activated, which in turn stabilizes p53. Protein levels of p53 may differ 
between cell lines and tissues due to efficiency and frequency of checkpoint activation. It has 
been shown in the past that checkpoint activation in mammalian cells after IR can differ 
between cell types (Gudkov and Komarova, 2003). These differences could be attributed to 
the tissue type, and the need for an active checkpoint in tissues that are exposed to a higher 
level of DNA damage. These differences in activation can also translate to differences in 
basal checkpoint protein levels, due to checkpoints that may be activated during DNA 
replication.  For cell lines and tissues, basal p53 protein levels may also differ due to cell and 
tissue type specific differences in total protein expression. Differentiated tissue types have 
displayed different profiles of gene expression and alternative splicing when analyzed 
through microarray analysis (Johnson et al., 2003). These basal differences in gene 
expression could account for differences in p53 expression levels. For the tissue samples, the 
external environment could have also affected the levels of p53 prior to sample collection. 
Samples obtained from gill tissue were directly exposed to the external environment, which 
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could have increased p53 due to constant activation. From these blots, it appears that brain 
and gill p53 is easily detected by the SulfoLink purified antibody in both cell lines and 
tissues. This high expression of p53 in the gill cells could be due to the exposure to the 
external environment. For the brain samples, the high levels of p53 could be attributed to an 
active checkpoint in the brain cells, due to the importance of this organ. In contrast, liver 
shows low expression of p53 in both cell line and tissues. This is an unexpected result, since 
one of the main liver functions is detoxification. A high level of p53 would be expected for a 
tissue that is more frequently exposed to toxicants. On the other hand, an unstressed liver 
may have constitutively lower levels of p53. For the spleen tissue, p53 is not detected by the 
SulfoLink purified antibody, but the RTS-11 cell line showed clear detection of p53. This 
difference could be due to the specific cell type that RTS-11 is derived from. RTS-11 is a 
macrophage-like cell line which was isolated from a long-term spleen haemopoietic culture, 
which is not representative of all the components of the spleen. The lack of p53 detection in 
the spleen tissue could be explained by the results of an early study into p53 expression in 
various human tissues (Rogel et al., 1985). They determined that p53 mRNA expression was 
heightened in the spleen, though the protein levels were barely detectable, due to high 
turnover of p53 in the spleen from rapid degradation. For the remaining cell lines, RTgut-GC 
also shows a clear detection of p53 whereas RTG-2 does not appear to show detection of p53 
with the SulfoLink purified antibody. For the RTgut-GC cell line, a higher level of p53 can 
be possibly explained by the origin of the cell line, as it was derived from gut epithelial cells. 
The constant exposure of this tissue type to the external elements, brought in through the 
digestive tract, may have lead to elevated basal p53 levels. The lack of p53 in the gonad-
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derived cell line, RTG-2, is unexpected but could possibly be due to the developmental stage 
of the original rainbow trout from which the cell line was derived.  RTplasma is not a cell 
line but was added to the panel based on the fact that p53 levels in plasma have been used in 
studies pertaining to DNA damage and cancer (Soussi, 2000). The SulfoLink purified 
antibody shows a good detection of p53 in RTplasma, indicating that plasma extraction may 
be an easy and non-lethal method of monitoring p53 levels in rainbow trout. The remaining 
tissue, heart, also shows a clear detection of p53. Together, these panels indicate that the 
expression pattern of p53 is similar between cell lines and tissues, which further supports the 
use of cell lines for future studies into p53 expression. It can also be seen that the SulfoLink 
purified antibody is better used for detection of p53 in cell lines, rather than in tissues, where 
a higher amount of background is present. 
3.4 Conclusion 
For this study, the objective was to generate a rainbow trout specific polyclonal p53 antibody 
that could be used in future studies of p53 expression. This antibody could also be used as 
part of a panel of antibodies for use in the larger goal of generating an environmental 
biomarker assay. From the results shown above, it is clear that the final SulfoLink purified 
antibody product is specific for detection of p53 in rainbow trout, though it is more 
compatible for detection of p53 in cell lines rather than tissues. In comparison with the 
human antibody, the SulfoLink purified antibody appears to be more consistent in its quality 




p53 protein expression is not induced in rainbow trout cell lines 
after exposure to DNA damage checkpoint inducing agents  
4.1 Introduction 
Eukaryotic cells grow and divide through a series of steps known as the cell cycle. The DNA 
in the original cell must be replicated to properly complete the cell cycle and produce two 
daughter cells. To ensure proper DNA replication and division of cells, mechanisms known 
as checkpoints are in place throughout the cell cycle. Specific cell cycle checkpoints can be 
activated by DNA damage or stalled replication forks to ensure high fidelity of DNA 
replication.  DNA maintenance checkpoints are composed of a network of proteins that are 
activated to preserve genomic integrity in the presence of genotoxic stress. Genotoxic stress 
can be present in the form of double strand breaks (DSBs), single strand breaks (SSBs), or 
stalled replication forks, which can alert certain sensor proteins to activate the DNA damage 
checkpoint (Nyberg et al., 2002). This usually involves the activation of several groups of 
proteins through a kinase cascade. The pathway begins with the detection of the initial DNA 
damage or replication stress and leads to the activation of downstream effector proteins, 
which will result in cell cycle arrest, DNA repair, or apoptosis (Sancar et al., 2004). 
The tumour suppressor protein p53 is an important factor in the DNA damage 
checkpoint pathway. It is a transcription factor that is involved in the transactivation of 
downstream factors which can help lead the cells to resolution of the checkpoint (Levine et 
al., 2004). As one of the main effector proteins in the checkpoint pathway, mutations in its 
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functional domains can lead to tumourigenesis and cancer. In over 50% of human tumours, 
mutations in p53 can be found, which lead to its inactivation. Due to its importance in cancer 
research, it has been extensively studied and well characterized in mammalian models; 
unfortunately, its regulation and mechanisms of action are not as well characterized for lower 
vertebrate species.  
Since p53 is a well known protein that is involved in cancer prevention, it has been 
suggested for use as a biomarker in aquatic toxicology studies, based on the assumption that 
the well characterized mammalian pathways are conserved in teleost species. While only a 
fraction of p53 studies are done in lower vertebrate species, these studies have been very 
important in highlighting some key differences in p53 function. Some of these studies do 
show that p53 is involved in pathways that are analogous to mammalian pathways, based on 
knockdown studies in fish models. Several of these studies have shown that p53 is necessary 
in the irradiation-induced apoptosis of cells in developing zebrafish (Berghmans et al., 
2005a; Inohara and Nunez, 2000).  Other studies in zebrafish have shown that reduced p53 
levels in embryos lead to lowered apoptotic response when exposed to DNA damaging 
agents (Stern and Zon, 2003). These studies display the importance of p53 in apoptosis, but 
they do not explore the mechanisms of activation and regulation of p53 for comparison with 
mammalian models. Certain studies, however, have highlighted some differences in the 
function and regulation of lower vertebrate p53, when compared to mammalian p53.  
In the mammalian model of p53 regulation, it is kept at low levels in the cell by its 
negative regulator mdm2. It has been shown in mice that overexpression of mdm2 can lead to 
a high rate of spontaneous tumour formation, possibly due to the down regulation of p53 
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(Jones et al., 1998). However, when a similar study was performed with zebrafish embyos, 
an increased rate of spontaneous tumour formation did not occur as a consequence of mdm2 
overexpression (Thisse et al., 2000). In terms of transcript regulation, it has been shown in 
mammalian models that p53 transcripts are upregulated after UV exposure but this same 
result was not seen in medaka cell lines or whole fish experiments, even at lethal doses of 
UV exposure (Chen et al., 2001). Instead, p53 transcript levels remained at a constant level 
after treatment in both in vitro and in vivo experiments. Following the cloning of the medaka 
p53 gene, it was also shown that N-methyl-N'-nitro-N-nitrosoguanidine (MMNG) induced 
tumors in medaka failed to show mutations in p53 mutational hotspots (Krause et al., 1997). 
Several studies in fish have also shown a lack of p53 mutation in a variety of tumours, which 
is unexpected due to a high prevalence of p53 mutations in mammalian tumours. In 
mammalian models, most studies focus on activation of p53 at the protein level, showing an 
induction of p53 protein after DNA damage, which is a well established mechanism. In 2006, 
this induction was shown to be absent in a rainbow trout liver cell line and in primary 
hepatocytes after treatment with model chemotherapeutics (Embry et al., 2006). Other 
studies have shown that p53 phosphorylation is increased at serine 15, but that total p53 
levels remained unchanged after DNA damage caused by hydroxyurea in urodele (Villiard et 
al., 2007) or aging related oxidative stress in ayu (Nagasaka et al., 2006). These studies 
highlight the need for further investigations into p53 regulation in lower vertebrate models, 
before drawing conclusions concerning its potential as an aquatic biomarker. 
The study presented here was performed for the purpose of further characterizing 
lower vertebrate p53 after exposure to genotoxic stress inducing agents. The rainbow trout 
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was chosen for this study due to its abundance in North American waters, its commercial 
importance, and the availability of rainbow trout cell lines. For this study, rainbow trout brain 
(RTbrain-W1) and rainbow trout gill (RTgill-W1) cell lines were treated with several types 
of DNA checkpoint inducing agents. The results obtained show that total p53 protein is not 
induced after treatments, even in the event of DNA damage, cell cycle arrest, or apoptosis.  
4.2 Results 
4.2.1 Rainbow trout p53 is not induced despite the presence of DNA damage caused 
by bleomycin 
Bleomycin is a radiomimetic agent that damages DNA by predominantly producing double 
stranded breaks (Povirk et al., 1977). It passed clinical trials in the 1970s (Blum et al., 1973) 
and it is still commonly used as a cancer therapeutic due to its ability to cause apoptosis in 
cells (Tounekti et al., 1993). In mammalian models, it has been shown that bleomycin 
induced apoptosis is p53 dependent (Araki et al., 1998) and that p53 is induced as a result of 
bleomycin treatment (Canman et al., 1994; Nelson and Kastan, 1994; Okudela et al., 1999). 
However, a study in 2006 showed that p53 was not induced in bleomycin treated primary 
hepatocytes from rainbow trout (Embry et al., 2006) despite its effect on mammalian cell 
lines. For the purposes of this study, two rainbow trout cell lines were used: RTbrain-W1 and 
RTgill-W1. Previously published work in our lab has shown that these two cell lines 
displayed distinct differing responses of the checkpoint protein Chk2 as a consequence of 
treatment with bleomycin (Steinmoeller et al., 2008). It was shown that Chk2 was induced in 
RTbrain-W1 cells as a result of bleomycin treatment. However, Chk2 was not induced in 
RTgill-W1 cells which showed constitutive expression of Chk2. These results indicated a 
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possible difference of checkpoint activation between cell types. As shown in Figures 4.1 and 
4.2, cells were treated with bleomycin for 0h, 1h, 4h, 8h, and 24h at concentrations of 3μg/ml 
or 18μg/ml. At both treatment concentrations, no induction of p53 is seen with either the 
RTbrain-W1 or RTgill-W1 cell line. To determine whether bleomycin was affecting the cells 
and inducing a checkpoint response, the detection of phosphorylated histone H2A (γH2AX) 
on serine 139 was added as a marker for DNA damage. Double stranded breaks have been 
shown to induce H2AX phosphorylation on serine 139 in several mammalian models 
(Rogakou et al., 1998) and this result has been replicated in a rainbow trout hepatoma cell 
line (RTH-149), specifically after IR treatment (Krumschnabel et al., 2010). The initial 
maximum concentration of bleomycin (18µg/ml) was near the amount necessary to cause 
~30% apoptosis in cultured cerebellar granule neurons of mice with wild type p53 treated for 
36 h with bleomycin (Araki et al., 1998). At this concentration, p53 was not induced and the 
rainbow trout cells did not undergo apoptosis (results not shown). To determine if the cells 
were more resistant to DNA damage by bleomycin, the dosing concentrations were increased 
up to 200µg/ml. With these new conditions, it can be seen through the increase in γH2AX 
that DNA is being damaged by treatment with bleomycin in a dose dependent manner, even 
though levels of p53 are not induced (Figure 4.3). This lack of induction differs from the 
expected result, based on mammalian models.  
4.2.2 Hydroxyurea causes cell cycle arrest without induction of p53 
Hydroxyurea is a antineoplastic agent that is commonly used to induce cell cycle arrest at the 






Figure 4.1 Detection of p53 in a time course of RTbrain-W1 cells treated with 
bleomycin for 24h. 
Western blots showing no time dependent induction of p53 over a 24h period after treatment 
with bleomycin at 3μg/ml and 18μg/ml. Protein extracts from RTbrains-W1 cells were 
loaded at 20µg per well in a 12% SDS-PAGE gel. Ponceau S staining and actin detection are 
provided as loading controls. p53 was detected using a polyclonal antibody to rainbow trout 
p53 that I produced (Chapter 3). Actin was detected with a monoclonal commercial antibody, 
specific to the conserved c-terminal region in the actin family and generated against a 
synthetic peptide, designed to be specific to multiple species and tissues (Sigma). A goat 






Figure 4.2 Detection of p53 in a time course of RTgill-W1 cells treated with bleomycin 
for 24h. 
Western blots showing no time dependent induction of p53 over a 24h period after treatment 
with bleomycin at 3μg/ml and 18μg/ml. Protein extracts from RTgill-W1 cells were loaded at 
20µg per well in a 12% SDS-PAGE gel. Ponceau S staining and actin detection are provided 
as loading controls. p53 was detected using a polyclonal antibody to rainbow trout p53 that I 
produced (Chapter 3). Actin was detected with a monoclonal commercial antibody, specific 
to the conserved c-terminal region in the actin family and generated against a synthetic 
peptide, designed to be specific to multiple species and tissues (Sigma). A goat anti-rabbit 





Figure 4.3 Detection of p53 and γH2AX in cells treated with high dose bleomycin for 
24h. 
Western blots showing no induction of p53 in both RTbrain and RTgill cells after treatment 
with bleomycin at various concentrations for 24h. The presence of DNA damage is shown by 
the induction of phosphorylated histone H2AX. Protein extracts were loaded at 20µg per well 
in a 12% SDS-PAGE gel. Ponceau S staining and actin detection are provided as loading 
controls. p53 was detected using a polyclonal antibody to rainbow trout p53 that I produced 
(Chapter 3). γH2AX was detected with a commercial antibody specific for the 
phosphorylated form of H2A at ser139 (Santa Cruz Biotech). Actin was detected with a 
monoclonal commercial antibody, specific to the conserved c-terminal region in the actin 
family and generated against a synthetic peptide, designed to be specific to multiple species 




enzyme ribonucleotide reductase, which causes replication forks to stall due to lack of 
deoxyribonucleotides. In mammalian cells lines, treatment with hydroxyurea has shown a 
time dependent induction of p53 up to 24 h (Ho et al., 2006b). For the dosing studies, several 
concentrations of hydroxyurea were used to produce cell cycle arrest in the cells. In Figure 
4.4, cell images taken after 3 days of treatment with 200mM hydroxyurea show that treated 
cultures are less confluent when compared to the untreated control. A proliferation assay, 
performed by Fanxing Zeng of Dr. Niels Bols’ lab, was done for both the gill and brain cell 
lines (Figure 4.5), which show that cell proliferation is stably arrested up to 9 days after 
treatment with 200mM hydroxyurea. These results show that the hydroxyurea treatment 
succeeded in arresting the cells. However, as with the bleomycin treatment, Figure 4.6 shows 
that levels of p53 do not increase after treatment with hydroxyurea even though cells are 
clearly growth arrested. It was next decided to look into p53 activation by phosphorylation. 
In the data sheet provided by Cell Signalling with their phosphorylated p53 antibody 
(specific for phosphorylated serine 392 of human p53), they showed that treatment of mink 
lung cells (MvlLu) with 20mM hydroxyurea for 16 h or 30 h was able to induce 
phosphorylation of p53 at serine 392. In our study, it was seen that treatment with 
hydroxyurea did not induce p53 phosphorylation on serine 392 (Figure 4.6). It is also seen 
that this phosphorylation on serine 392 is present in control cells, indicating that it is 






Figure 4.4 Appearance of cells treated with 200mM hydroxyurea for 3 days. 
Phase-contrast microscopy appearance of RTbrain-W1 and RTgill-W1 cultures. 
Photomicrographs were taken of cultures treated with 200mM hydroxyurea for 3 days for 
comparison with untreated control cultures at a magnification of 100x. These images show 
that the treated cultures are less confluent, when compared to control cultures. Cells were 
seeded in 25cm2 flasks at either 1.5 x 106 (RTbrain-W1) or 3 x 106 (RTgill-W1) cells per 
flask, which is half of the usual plating densities to allow for obvious differences in cell 






Figure 4.5 Growth curves for cells treated with 200mM hydroxyurea. 
Growth curves showing a growth arrest for both RTbrain-W1 and RTgill-W1 cells treated 
with 200mM hydroxyurea when compared to untreated control cultures. Cells were counted 
at the indicated time points using a Coulter Counter (Beckman Coulter). Error bars represent 




Figure 4.6 Detection of p53and p-p53 (ser392)  in cells treated with hydroxyurea for 
24h. 
 Western blots showing no induction of total p53 or phosphorylated  p53 (Ser392) in both 
RTbrain and RTgill cells after treatment with hydroxyurea at various concentrations for 24h. 
Protein extracts were loaded at 20µg per well in a 12% SDS-PAGE gel. Ponceau S staining 
and actin detection are provided as loading controls. p53 was detected using a polyclonal 
antibody to rainbow trout p53 that I produced (Chapter 3). Phosphorylated p53 was detected 
with a commercial antibody specific for the phosphorylated form of p53 at ser392 (Cell 
Signaling). Actin was detected with a monoclonal commercial antibody, specific to the 
conserved c-terminal region in the actin family and generated against a synthetic peptide, 
designed to be specific to multiple species and tissues (Sigma). A goat anti-rabbit IgG HRP 
conjugated secondary was used for detection (Bio-Rad). 
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4.2.3 ATM/ATR activation 
Given that γH2AX is being phosphorylated as a result of DNA damage by bleomycin in the 
rainbow trout cells, I also wanted to determine if other components of the DNA damage 
pathway were also being activated. This could help determine if the pathway is being 
activated similarly to mammalian models, which would help characterize the differences seen 
thus far for rainbow trout p53. Determining if proteins are active in the DNA damage 
checkpoint could also be useful in finding potential biomarkers for the generation of an 
environmental biomarker assay, which was discussed in Chapter 3. Two of the major kinases 
in the DNA damage pathway are ATM (Ataxia Telangiectesia Mutated) and ATR (ATM and 
Rad3 related). Activation of these kinases plays a major role in the DNA damage checkpoint 
pathway (Stokes et al., 2007). In the mammalian pathway, ATM and ATR are activated 
upstream of p53. By looking at phosphorylation of its downstream targets, activation of the 
ATM/ATR pathways can be inferred. For the bleomycin and hydroxyurea treated samples, it 
can be seen that downstream substrates of ATM/ATR are being phosphorylated upon 
treatment with either bleomycin or hydroxyurea (Figure 4.7), though the effect does not 
appear to be dose dependent at the concentrations tested in RTbrain-W1 cells. For the 
treatments in the brain cell line, a difference in profile can be seen between bleomycin treated 
samples and hydroxyurea treated samples; this difference in profile between the two 
treatments is not seen in the gill cell line. Differences in basal profiles, as well as dosed 
profiles, also exist between the two cell lines, indicating cell line specific differences in 
phosphorylation states before and after treatments. These differences display the importance 




Figure 4.7 Detection of phosphorylated downstream substrates of ATM/ATR after 
treatment with bleomycin or hydroxyurea for 24h. 
Cells were treated with different doses of bleomycin or hydroxyurea for 24h. Proteins were 
loaded at 20µg per well in a 12% SDS-PAGE gel. Ponceau S staining and actin detection are 
provided as loading controls. The treatments caused a distinct change in phosphorylation 
profile for the ATM/ATR substrates. These treatments also seem to affect phosphorylation in 
a manner that is dependent on both the reagent and cell type used. The blots were detected 
with Phospho-(Ser/Thr) ATM/ATR Substrate antibody (Cell Signalling) which detects 
endogenous levels of proteins containing the phosphorylated ATM/ATR substrate motif. 
Actin was detected with a monoclonal commercial antibody, specific to the conserved c-
terminal region in the actin family and generated against a synthetic peptide, designed to be 
specific to multiple species and tissues (Sigma). A goat anti-rabbit IgG HRP conjugated 
secondary was used for detection (Bio-Rad). 
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between cell types. Depending on the protein of interest, certain cell lines may not show 
activation of the protein through phosphorylation. For the environmental biomarker project 
outlined in Chapter 3, the assay should have the capacity to examine several tissue types, to 
account for differences in activation between tissues. The use of one tissue type does not 
generate a profile specific enough to determine the type and severity of DNA damage. These 
results also confirm that the DNA damage pathway is being activated by both treatments and 
in both cell types, even though p53 is not being induced. 
4.2.4 Methyl methane sulfonate (MMS) induces cell death without induction of p53 
MMS is a DNA-akylating agent which methylates DNA. It has been shown to cause 
apoptosis and formation of γH2AX foci in mammalian cell lines (Zhou et al., 2006). In a 
mammalian hepatoblastoma cell line, both lethal and non lethal doses of MMS caused an 
induction in total p53 (Jiang et al., 1999). For this study, cells were dosed for two different 
time points: 4h and 24h. The 4h incubation represented a non-lethal treatment as cell death 
was not observed. The 24h treatment represented a lethal treatment condition as dead cells 
were clearly visible in the treated cultures. In contrast to the mammalian model, my 
preliminary results show that p53 in both brain and gill cell lines was not induced by either 
non-lethal (Figure 4.8) or lethal treatments with MMS (Figure 4.9). An induction of γH2AX 
is detected in the lethal treatments for RTbrain-W1 cells, though no increase is seen in the 
non-lethal treatments. In a study by Burma et al. in 2001, they showed that MMS treatment 
did not induce phosphorylation of H2AX on serine 139 in spontaneously immortalized 
mouse fibroblasts. Only double strand break inducing treatments caused a noticeable 




Figure 4.8 Detection of p53 and γH2AX in cells treated with methyl methanesulfonate 
(MMS) for 4 h, representing non-lethal treatment. 
Western blots showing no induction of p53 in both RTbrain and RTgill cells after treatment 
with methyl methanesulfonate at various concentrations for 4h. This treatment represents a 
non-lethal treatment of cells. There is no induction of γH2AX. Proteins were loaded at 20µg 
per well in a 12% SDS-PAGE gel. Ponceau S staining and actin detection are provided as 
loading controls. p53 was detected using a polyclonal antibody to rainbow trout p53 that I 
produced (Chapter 3). γH2AX was detected with a commercial antibody specific for the 
phosphorylated form of H2A at ser139 (Santa Cruz Biotech). Actin was detected with a 
monoclonal commercial antibody, specific to the conserved c-terminal region in the actin 
family and generated against a synthetic peptide, designed to be specific to multiple species 






Figure 4.9 Detection of p53 and γH2AX in cells treated with methyl methanesulfonate 
(MMS) for 24h, representing lethal treatment. 
Western blots showing a no induction of p53 in both RTbrain and RTgill cells after treatment 
with methyl methanesulfonate at various concentrations for 24h. The higher doses represent a 
lethal dosing treatment of the cells. The presence of DNA damage is shown by the induction 
of phosphorylated histone H2AX in the RTbrain-W1 cells. Proteins were loaded at 20µg per 
well in a 12% SDS-PAGE gel. Ponceau S staining and actin detection are provided as 
loading controls. p53 was detected using a polyclonal antibody to rainbow trout p53 that I 
produced (Chapter 3). γH2AX was detected with a commercial antibody specific for the 
phosphorylated form of H2A at ser139 (Santa Cruz Biotech). Actin was detected with a 
monoclonal commercial antibody, specific to the conserved c-terminal region in the actin 
family and generated against a synthetic peptide, designed to be specific to multiple species 




through base excision repair and since MMS does not predominantly produce DSBs, it is 
possible that the slight appearance of γH2AX in the lethal treatment of RTbrain-W1 cells 
may be due to transiently appearing double strand breaks that are occurring due to the cells 
inability to keep up with repairs. The lack of γH2AX induction in the RTgill-W1 cells could 
indicate a more efficient DNA damage response, which is repairing the DNA at a quicker 
rate, leading to less detection of DSBs. These initial results also show that the lethal doses of 
MMS seem to generate a different profile of p53 detection in the rainbow trout brain cell line 
(Figure 4.9). For doses above 0.01% for 24h treatments of the RTbrain-W1 cell line, the 
main p53 band is decreased, while an extra band appears approximately 10 kDa lower. This 
initial result may represent modifications that are happening to p53 in dying cells. The 
absence of this result in the RTgill-W1 cells may be caused by a difference in the pathways 
activated by MMS, as the RTbrain-W1 cells appear to have an activated DSB response that is 
absent in the RTgill-W1 cells. 
4.3 Discussion 
In mammalian species, p53 is a highly conserved protein that plays a key role in tumour 
suppression and is an important factor in research towards cancer prevention and treatment. 
In lower vertebrates however, the mechanisms behind its regulation and activation are mostly 
unexplored. It has been suggested in the past that p53 would make a good molecular 
biomarker for aquatic toxicology studies based on sequence comparison of fish p53 and 
mammalian p53 sequences (Bhaskaran et al., 1999), though actual functional data for p53 in 
fish is limited in contrast to mammalian models. Previous studies have highlighted some 
differences in the function and regulation of p53 in lower vertebrate species, compared to 
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mammalian models (Krause et al., 1997; Chen et al., 2001; Embry et al., 2006), which 
emphasizes the need for more research into p53 and its use as a potential biomarker for 
environmental carcinogenesis. 
To study p53 protein expression, a polyclonal p53 antibody was generated from 
recombinantly expressed rainbow trout p53. This antibody was shown to detect p53 in both 
human and rainbow trout cells lines (Chapter 3). To examine p53 activation, two different 
cell lines were dosed with the chemotherapeutic agent bleomycin. In mammalian models, 
bleomycin has been shown to produce double strand breaks in DNA, which then lead to 
induction of p53 (Canman et al., 1994; Nelson and Kastan, 1994; Okudela et al., 1999). In 
contrast, a study in rainbow trout has shown that primary hepatocytes do not exhibit an 
induction in p53 after treatment with bleomycin after 24 hours (Embry et al., 2006). To 
examine this further, two rainbow trout cell lines that were unrelated to the liver were chosen 
for study. These two cell lines have shown interesting results regarding Chk2, which acts 
upstream of p53 in the DNA damage checkpoint pathway, that indicated different cell line 
specific mechanisms of activation and control for Chk2 in the presence of bleomycin 
(Steinmoeller et al., 2008). The use of these cell lines would help determine if the lack of p53 
induction in primary hepatocytes was a tissue specific phenomenon. For both RTbrain-W1 
and RTgill-W1 cell lines, the results show that p53 is not induced up to 24 hours after 
treatment with either 3µg/ml or 18 µg/ml bleomycin (Figure 4.1 and Figure 4.2). Increased 
concentrations of bleomycin (up to 200 µg/ml) also did not induce p53, but histone H2A was 
shown to be phosphorylated on serine 139 in a dose dependent manner (Figure 4.3). This 
indicated that the treatment of the cells was inducing DNA damage and initiating the DNA 
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damage checkpoint pathway. The lack of increase in p53 infers that this pathway acts 
independently of p53, or that p53 is activated through a different mechanism. Post 
translational modifications such as phosphorylation or acetylation of p53 may be the main 
method of control, independent of total p53 induction. 
To further explore the differences between rainbow trout p53 and mammalian p53, 
the cells were dosed with hydroxyurea, which initiates a checkpoint through DNA replication 
fork stalling. Hydroxyurea treatment has shown induction of total p53 and cell cycle arrest in 
mammals (Ho et al., 2006a; Taylor et al., 1999). In human and mouse fibroblasts, cell cycle 
arrest caused by hydroxyurea has been shown to be p53 dependent. In wild type cells, p53 
was induced by the hydroxyurea treatment and cell cycle arrest was achieved, whereas p53 
null cells were able to undergo mitosis despite treatment with hydroxyurea (Taylor et al., 
1999). According to the data sheet that accompanied the phospho-specific p53 antibody for 
serine 392 (Cell Signalling), treatment of mink lung cells (MvlLu) with 20mM hydroxyurea 
also showed a strong induction of p53 phosphorylation on serine 392 after either 16 or 30 
hours of treatment.  Unlike the mammalian models, hydroxyurea treatments did not increase 
total p53 or phosphorylated p53 at serine 392 for treatments up to 200mM (Figure 4.6). The 
phosphorylation of p53 at serine 392 also appeared in the untreated control samples, 
indicating a constant level of basal phosphorylation at that site for both RTbrain-W1 and 
RTgill-W1 cell lines. Despite this lack of induction and phosphorylation of p53, cells were 
still visibly arrested after treatment (Figure 4.4), even with low concentrations of 
hydroxyurea. Through a cell proliferation assay, it was determined that cells remain arrested 
up to 9 days after treatment with 200mM hydroxyurea, even though p53 is not being induced 
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(Figure 4.5). These results indicate that the cells were arrested, independent of p53 induction, 
which differs from the mammalian model of cell cycle arrest after treatment with 
hydroxyurea. 
To further examine the effects of treatment with bleomycin and hydroxyurea, an 
ATM/ATR phosphorylated substrate antibody was used to detect changes in phosphorylation 
states of downstream substrates of ATM/ATR. The results show an obvious difference in 
phosphorylation profiles between control and treated samples. There is also a difference in 
profile between the two cell types, for both control and treated samples. This indicates that 
there are cell line specific differences in basal phosphorylation states of proteins, as well as 
differences in phosphorylation substrates when a checkpoint is induced. The difference 
between the basal profiles is to be expected, as each cell line is generated from a specific cell 
type from a particular tissue. Different tissues are known to have different basal protein 
expression profiles which could affect the basal phosphorylation states of proteins due to 
upregulation of certain kinases in different cell types. As for the differences in 
phosphorylated substrates between the two treatments, this is likely due to the different types 
of checkpoints that become activated. Whereas bleomycin can act anytime during the cell 
cycle to damage the DNA and produce double-stranded breaks, hydroxyurea usually 
generates replication blocks during S-phase. It has also been shown that hydroxyurea induced 
p53 accumulation can be generated through mechanisms that are distinct from the DNA 
damage checkpoint (Ho et al., 2006a). This would support the hypothesis that both 
treatments are activating their respective pathways, possibly independent of p53 or through a 
mechanism separate from induction of total p53 accumulation. 
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For a third type of DNA damage, MMS was used to generate replication blocks 
caused by methylation of the DNA. It has been shown in the past that MMS was able to 
induce total p53 in the Hep G2 human hepablastoma cell line after treatment with both lethal 
and non-lethal doses (Jiang et al., 1999). In this preliminary study, dosing studies were 
performed under two types of conditions: non-lethal and lethal. For the non-lethal treatment, 
cells were incubated with MMS for only 4 h, whereas the lethal treatment lasted for 24h, 
resulting in visible dose dependent cell death. Initial results show that both non-lethal (Figure 
4.8) and lethal treatment (Figure 4.9) conditions produced no induction of p53 in either cell 
line. Under the lethal treatment conditions, a very mild increase of γH2AX can be seen in 
RTbrain-W1, though this increase is lacking in the non-lethal treatment samples. Though foci 
of γH2AX have been detected after MMS treatment in human amnion epithelial cells (Zhou 
et al., 2006), it has also been shown that γH2AX is only phosphorylated after treatment with 
double strand break inducing agents (Burma et al., 2001). MMS is a DNA alkylating agent 
and DSBs are not the main type of damage produced but the appearance of γH2AX in 
RTbrain-W1 cells could be a by-product of repair. It can also be seen that lethal treatments 
produced a slight decrease in p53 in the brain cells (Figure 4.9), but this decrease is 
accompanied by the appearance of a lower band in the 0.02% and 0.03% treatments that 
coincides with the decrease in the main p53 band. It has been previously shown that p53 is 
cleaved by caspases in apoptotic cells, which generates fragments that localize to the 
mitochondria to induce transcription-independent changes that aid in apoptosis of the cells 
(Sayan et al., 2006). Based on the profiles of fragmentation seen in the Sayan et al. study, 
this lower band could be due to fragmentation of the original p53 protein. One of the main 
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fragments that appeared in the fragmented profile of the mitochondrial study appears to be 
similar in size to the lower band seen in the brain cells after lethal MMS treatments. These 
preliminary results could possibly indicate that p53 is still being activated for apoptosis 
through fragmentation, but not for its well known function as a transcription factor. These 
initial results with MMS treatment indicate some cell line specific differences pertaining to 
p53 fragmentation, as well as γH2AX induction. These differences may be a result of 
variation in the efficiency of DNA repair and the initiation of apoptosis in different cell 
types. As mentioned earlier, a more efficient DNA damage response could account for 
quicker repair in the RTgill-W1 cells, which could decrease the amounts of DSBs. This more 
efficient DNA damage response could have evolved for the gill cells due to their constant 
direct exposure to the external environment. This constant exposure could have aided in 
selecting for a highly efficient DNA damage response, to deal with the constant onslaught of 
DNA damage. These results pertaining to MMS treatments are preliminary, and need to be 
repeated further for confirmation of the results before any definite conclusions can be drawn. 
4.4 Conclusions 
From this study, it can be seen that the commonly observed induction of p53 in mammalian 
models is absent from the rainbow trout model after checkpoint induction with bleomycin, 
hydroxyurea, and MMS. These treatments have been shown to induce p53 in mammalian 
models, leading to either cell cycle arrest or apoptosis but the induction of p53 is not seen in 
this study, even though the effects of the treatments can be seen. In the case of bleomycin, 
the DNA damage being produced is evident in the dose dependent accumulation of γH2AX. 
For hydroxyurea treatment, cells are clearly arrested and fail to proliferate in comparison to 
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their untreated counterparts. With MMS, treatments for 24 hours produced a high degree of 
apoptosis at the higher doses, along with a slight induction of γH2AX in the case of RTbrain-
W1. All of these treatments produced results indicating activation of their respective 
checkpoints yet p53 levels remain constant. This result indicates that the DNA checkpoints 
may function independently of p53, or that p53 is regulated in a manner that does not result 
in accumulation of total p53 protein. The activation of p53 may be occurring through 
phosphorylation, acetylation, or fragmentation, similar to mammalian models, but does not 
result in an accumulation of total p53. A difference in p53 regulation and function between 
mammalian models and lower vertebrate models is also supported by a study regarding the 
phylogenetic analysis of p53 (Pintus et al., 2007). The study showed that the rate of fixation 
of nonsynonymous substitutions over synonymous substitutions significantly increased when 
the ancestors of amphibians started moving onto land. They hypothesized that the more 
hostile land environment required an increased role for p53 as a tumour suppressor, in 
comparison to their previous aquatic environment. Whether it is a difference in activation, 
regulation or function of p53, the results of this study show that p53 may not be an ideal 
biomarker for genotoxic stress in lower vertebrate species. However, the dose dependent 
increase of γH2AX was apparent in both RTbrain-W1 and RTgill-W1 cells after treatment 
with bleomycin, indicating its potential as a possible biomarker of DNA damage in rainbow 
trout. While lack of induction in total p53 indicates a lack of biomarker potential, its 
differences from the mammalian model are definitely a point of interest for future studies. It 
is evident that further study needs to be done in order to elucidate the mechanisms behind the 
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regulation and function of p53 in rainbow trout, as it appears to function differently than 





The study outlined in Chapter 3, is the first to generate a rainbow trout specific polyclonal 
antibody and it has proved useful in the studies outlined in Chapter 4, that have brought to 
light interesting results regarding the potential regulation, activation, and function of p53 in 
rainbow trout.  
The rainbow trout specific p53 antibody was originally generated for use in dosing 
studies of rainbow trout cell lines, with the intent of subsequent use in the development of a 
potential environmental biomarker assay. However, the results of our dosing studies indicate 
that rainbow trout p53 may not be an ideal biomarker of DNA damage. With the study 
outlined in Chapter 4, it is apparent that rainbow trout p53 is not induced after treatment with 
agents that are known to cause a DNA damage response due to various different 
mechanisms. Under treatment conditions causing double-stranded breaks, cell cycle arrest, 
and apoptosis, the levels of p53 were not induced, contrary to the known mechanisms of p53 
activation in mammalian models. However, these studies have revealed interesting results 
that could be useful in the future directions of this project. For the detection of treatment 
induced double stranded breaks in the rainbow trout cells, the induction of γH2AX could 
clearly be seen, indicating that γH2AX shows good promise as a biomarker of DNA damage 
in rainbow trout. Along with the clear induction, γH2AX would also be useful as a biomarker 
due to its specific induction in the presence of DSBs, allowing for determination of the 
possible origins of damage induction. Along with the determination of γH2AX as a potential 
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biomarker, ATM/ATR and their downstream substrates were also revealed to be activated in 
the DNA damage response. As with γH2AX, a clear induction in ATM/ATR activity could 
be seen after treatment, as judged by an induction of phosphorylation in ATM/ATR 
substrates that was not present in the untreated control. There were also differences in 
profiles of phosphorylated substrates depending on the type of treatment. These results 
indicate that ATM/ATR are activated and would also be good biomarkers of DNA damage. 
In light of the treatment dependent differential activation of downstream substrates, 
substrates of ATM/ATR could also be tested for biomarker potential in future studies. The 
preliminary results in the MMS study also displayed interesting results that could be of 
interest for future studies. In the apoptotic RTbrain-W1 cultures, the appearance of a band 
around ~10kDa below the p53 band was of interest due to the fact that it coincided with a 
decrease in the main p53 band. As discussed in Chapter 4, this lower band could be 
indication of p53 activation through fragmentation by caspases, for localization to the 
mitochondria.  
This thesis, along with other published research into non-mammalian p53, suggests 
that the mechanisms involved in non-mammalian p53 regulation vary between organisms and 
show varying levels of differences to mammalian p53. Non-mammalian model organisms are 
often used as models for toxicology and carcinogenesis, and drawing conclusions based on 
the well known mechanisms of mammalian p53 could lead to erroneous assumptions. Further 
studies of p53 in non-mammalian models are required to better understand the mechanisms 
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